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ABSTRACT 
 
Genetic differences in sensitivity to environmental carcinogens are the most important 
factors in the estimate risk of human cancer. Individual susceptibility to oesophageal 
cancer may be partly due to genetic differences in genes controlling the metabolic 
balance between the oxidation (activation) and conjugation (detoxification) of 
procarcinogens. The objectives of this prospective case-control study were to investigate 
genetic differences among Sudanese patients with oesophageal cancer in comparison with 
healthy controls using single nucleotide polymorphisms (SNPs) as genetic markers and 
polymerase chain reaction based restriction fragment length polymorphism as genotyping 
method and to correlate between those polymorphisms and the risk of oesophageal cancer 
in Sudan. Alcohol-metabolizing genes (ADH and ALDH2) and xenobiotic-metabolizing 
genes (CYP3A5, GSTM1, GSTT1 and SULT1A1) have been studied for this purpose. 
One hundred and thirty four (134) oesophageal cancer patients who underwent 
oesophagoscopy at the National Centre of Gastrointestinal and Liver Diseases, Ibn Sina 
Hospital and Khartoum Teaching Hospital and 233 healthy Sudanese volunteers were 
studied during the period (2001-2005). Blood samples were collected from all subjects in 
EDTA coated tubes. Genomic DNA was isolated and assessed for genetiC variations 
using eight differEnt polymorphic loci of the respective genes.  Eight primer pairs were 
designed according to published sequence data for exon 3 and exon 9 in ADH2, exon 8 in 
ADH3, exon12 in ALDH2, intron 3 in CYP3A5, exon 7 in SULT1A1 and in the regions 
containing the d%letion in both GSTTM1 and GSTT1 genes. DNA was amplified using 
polymerase chain reaction and the PCR products were inves4igated for SNP, using RFLP 
procedures. The different genotypes were scored for each locus and data were analyzed 
using computer software SPSS for Windows. Allelic frequencies for each gene in patients 
and controls were computed using the genotype data and the results were used for further 
analysis. The odd-ratios were estimated by the logistic regression model, assuming 95% 
as the confidence interval (CI).  All loci were polymorphic and two alleles per locus were 
detected. Our findings showed that there are no significant differences in the frequency 
distribution of ADH2, ALDH2, CYP3A5 and SULT1A1 Alleles between oesophageal 
cancer p`tients and healthy controls (P>0.05). The study did indicate a significant 
 VI
difference in GSTM1 and GSTT1 null-genotypes between patients and controls (P<0.05). 
In conclusion, our results cnnfirmed the usefulness of SNPs for research on genetic 
variations and relationships to cancer suscepTibility. The present study showed for the 
first time the alleLic frequencies of ADH, ALDH2, CYP3A5, GSTM1, GSTT1 and 
SUL1A1 in Sudanese populations. 
 
Keywords: Oesophageal cancer, Genetic polymorphism, SNPs, PCR-RFLP, Alcohol-
metabolizing enzymes, Xenobiotic-metabolizing enzymes. 
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 ﻤﻠﺨﺹ ﺍﻟﺩﺭﺍﺴﺔ
 
ﺭ ﺍﻻﺨﺘﻼﻓﺎﺕ ﺍﻟﻭﺭﺍﺜﻴﺔ ﻓﻲ ﺍﻟﺤﺴﺎﺴﻴﺔ ﻟﻠﻤﺴﺭﻁﻨﺎﺕ ﺍﻟﺒﻴﺌﻴﺔ ﻤﻥ ﺍﻫﻡ ﻋﻭﺍﻤل ﺘﺤﺩﻴﺩ ﺨﻁﺭ ﺍﻻﺼﺎﺒﺔ ﺒﺎﻟﺴﺭﻁﺎﻥ ﻓﻲ ﺘﻌﺘﺒ
ﺯﻥ  ﻓﻲ ﺍﻟﺠﻴﻨﺎﺕ ﺍﻟﺘﻲ ﺘﺤﻜﻡ ﺍﻟﺘﻭﺍﺍﻻﺨﺘﻼﻓﺎﺕ ﺍﻟﻭﺭﺍﺜﻴﺔﺔ ﺍﻟﻔﺭﺩ ﻟﻼﺼﺎﺒﺔ ﺒﺴﺭﻁﺎﻥ ﺍﻟﻤﺭﺉ ﻋﻠﻰ ﻗﺩ ﺘﻌﺘﻤﺩ ﻗﺎﺒﻠﻴ. ﺍﻻﻨﺴﺎﻥ
ﺍﻟﻰ ﺘﺤﺩﻴﺩ   ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔﻫﺩﻓﺕ.  ﺍﺤﺔ ﺍﻟﺴﻤﻴﺔ ﻟﻠﻤﺴﺭﻁﻨﺎﺕ ﺍﻟﻤﻭﺠﻭﺩﺓ ﻓﻲ ﺍﻟﺒﻴﺌﺔﺯﺍﻻﻴﻀﻲ ﻤﺎﺒﻴﻥ ﺍﻻﻜﺴﺩﺓ ﺍﻟﻤﻨﺸﻁﺔ ﻭﺍ
ﻭﺫﻟﻙ ﺒﺎﺴﺘﺨﺎﺫ ﺍﻟﺠﻴﻨﺎﺕ , ﻜﻤﺠﻤﻭﻋﺔ ﻀﺎﺒﻁﺔ ﺒﻤﺘﻁﻭﻋﻴﻥ ﺍﺼﺤﺎﺀ  ﻤﻘﺎﺭﻨﺔﻋﻨﺩ ﻤﺭﻀﻰ ﺴﺭﻁﺎﻥ ﺍﻟﻤﺭﺉﺍﻟﺘﺒﺎﻴﻥ ﺍﻟﺠﻴﻨﻲ 
  ﺍﻟﺘﻔﺎﻋل ﺍﻟﺒﻠﻤﺭﻱ ﺍﻟﻤﺘﺴﻠﺴل ﻭﺭﺍﺜﻴﺔ ﻭﺍﺴﺘﻌﻤﺎل ﻁﺭﻴﻘﺔ ﺍﻟﺘﺤﻠﻴل ﺍﻟﺠﻴﻨﻲ ﺍﻟﻤﻌﺘﻤﺩﺓ ﻋﻠﻰﻜﻤﺅﺸﺭﺍﺕﻋﺩﻴﺩﺓ ﺍﻻﺸﻜﺎل 
ﻓﻲ ﺨﻁﺭ ﺍﻻﺼﺎﺒﺔ ﺒﺴﺭﻁﺎﻥ ﺍﻟﺘﺒﺎﻴﻥ ﺍﻟﺠﻴﻨﻲ  ﻜﻤﺎ ﻫﺩﻓﺕ ﺍﻟﺩﺭﺍﺴﺔ ﺍﻟﻰ ﻤﻌﺭﻓﺔ ﺩﻭﺭ . ﻓﻲ ﺘﺤﺩﻴﺩ ﺍﻟﻨﻤﻁ ﺍﻟﻭﺭﺍﺜﻲRCPﺍل
 2HDLA dna HDA()ِ ﺍﻴﺽ ﺍﻟﻜﺤﻭلﺘﻌﻤل ﻋﻠﻰﺎﺕ ﺍﻟﺘﻲ ﻨﻟﺠﻴﻟﻬﺫﺍ ﺍﻟﻐﺭﺽ ﺘﻤﺕ ﺩﺭﺍﺴﺔ ﺍ. ﺍﻟﻤﺭﺉ ﻓﻲ ﺍﻟﺴﻭﺩﺍﻥ
 . ﻓﻲ ﺍﻻﻨﺴﺎﻥ )1A1TLUS dna 1TTSG ,1MTSG ,5A3PYC(ﻭﺍﻟﺠﻴﻨﺎﺕ ﺍﻟﺘﻲ ﺘﻌﻤل ﻋﻠﻰ ﺍﻴﺽ ﺍﻟﺴﻤﻭﻡ
 ﻤﺭﻴﺽ ﺒﺴﺭﻁﺎﻥ ﺍﻟﻤﺭﺉ  ﺘﻡ ﺍﺠﺭﺍﺀ ﻤﻨﻅﺎﺭ ﺍﻟﻤﺭﺉ  ﻟﻬﻡ ﺒﻭﺤﺩﺓ ﺍﻟﻤﻨﺎﻅﻴﺭ ﺒﻜل ﻤﻥ ﺍﻟﻤﺭﻜﺯ 331ﺸﻤﻠﺕ ﺍﻟﺩﺭﺍﺴﺔ 
 ﻤﺘﻁﻭﻋﻴﻥ ﺍﺼﺤﺎﺀ 332ﻭ ﻭ ﻤﺴﺘﺸﻔﻰ ﺍﻟﺨﺭﻁﻭﻡ ﺍﻟﺘﻌﻠﻴﻤﻲ( ﺍﺒﻥ ﺴﻴﻨﺎﺀﻤﺴﺘﺸﻔﻰ )ﺍﻟﻘﻭﻤﻲ ﻻﻤﺭﺍﺽ ﺍﻟﺠﻬﺎﺯ ﺍﻟﻬﻀﻤﻲ 
ﺘﻡ ﺠﻤﻊ ﻋﻴﻨﺎﺕ ﻤﻥ ﺍﻟﺩﻡ ﻤﻥ ﺠﻤﻴﻊ ﺍﻻﻓﺭﺍﺩ ﺜﻡ ﺍﺴﺘﺨﻠﺹ . (5002-1002) ﻭﺫﻟﻙ ﺨﻼل ﺍﻟﻔﺘﺭﺓ ﻜﻤﺠﻤﻭﻋﺔ ﻀﺎﺒﻁﺔ
 ﺒﺎﺴﺘﻌﻤﺎل ﻁﺭﻴﻘﺔ ﺍﻟﺘﺤﻠﻴل ﺍﻟﺠﻴﻨﺎﺕ ﻋﺩﻴﺩﺓ ﺍﻻﺸﻜﺎل ﻭﺘﻡ ﺘﺤﻠﻴﻠﻪ ﻓﻲ ﻤﻭﺍﻗﻊ ANDﺍﻟﺤﺎﻤﺽ ﺍﻟﻨﻭﻭﻱ ﻨﺎﻗﺹ ﺍﻻﻜﺴﺠﻴﻥ ﺍل
ﻟﻡ ﺘﻅﻬﺭ ﻫﺫﻩ ﺍﻟﺩﺍﺴﺔ ﺍﻱ .  ﺘﻡ ﺭﺼﺩ ﻭﺘﺤﻠﻴل ﺍﻟﺒﻴﺎﻨﺎﺕ ﺍﻟﻨﺎﺘﺠﺔ ﺍﺤﺼﺎﺌﻴﺎ. ﻓﻲ ﺘﺤﺩﻴﺩ ﺍﻟﻨﻤﻁ ﺍﻟﻭﺭﺍﺜﻲRCPلﺍﻟﻤﻌﺘﻤﺩﺓ ﺍ
 dna HDA( ﻟﺠﻴﻨﺎﺕ ﺍﻴﺽ ﺍﻟﻜﺤﻭلﺍﻟﺸﺎﺫﺓ ﻓﻲ ﺍﻟﺘﻭﺯﻴﻊ ﺍﻟﺘﻜﺭﺍﺭﻱ ﻟﻼﺸﻜﺎل ﺼﺤﺎﺀﺍﺨﺘﻼﻑ ﺒﻴﻥ ﺍﻟﻤﺭﻀﻰ ﻭﺍﻻ
ﻟﻼﺸﻜﺎل   ﺍﻟﺘﻜﺭﺍﺭﻱ ﺒﻴﻨﻤﺎ ﺍﻅﻬﺭﺕ ﺍﻟﺩﺭﺍﺴﺔ ﺍﺨﺘﻼﻑ ﺒﻨﺴﺒﺔ ﻜﺒﻴﺭﺓ ﺒﻴﻥ ﺍﻟﻤﺭﻀﻰ ﻭﺍﻻﺼﺤﺎﺀ ﻓﻲ ﺍﻟﺘﻭﺯﻴﻊ )2HDLA
ﺘﻌﺘﺒﺭ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﺍﻭل ﺘﻘﺭﻴﺭ ﻋﻠﻤﻲ .  )1TTSG dna 1MTSG(  ﻟﻠﺠﻴﻨﺎﺕ ﺍﻟﺘﻲ ﺘﻌﻤل ﻋﻠﻰ ﺍﻴﺽ ﺍﻟﺴﻤﻭﻡﺍﻟﺸﺎﺫﺓ
ﻟﺠﻴﻨﺎﺕ ﺍﻟﺘﻲ ﺘﺤﻜﻡ ﺍﻴﺽ ﺍﻟﻜﺤﻭل ﻭﺍﻟﺠﻴﻨﺎﺕ ﺍﻟﺘﻲ ﺘﻌﻤل ﻋﻠﻰ  ﻻﻟﻴﻼﺕ ﺍﻓﻲ ﺍﻟﺴﻭﺩﺍﻥ ﺤﻭل ﺘﺤﺩﻴﺩ ﺍﻟﺘﻭﺯﻴﻊ ﺍﻟﺘﻜﺭﺍﺭﻱ
  .ﺍﻴﺽ ﺍﻟﺴﻤﻭﻡ
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Introduction & Literature Review 
 
1.1. Oesophageal cancer: 
Oesophageal cancer is the cancer of the tube connecting the mouth to the stomach. 
Cancer of the oesophagus has been reported as the ninth most common cancer and ranks as 
the sixth most frequent cause of cancer death in the world. It also constitutes 7% of all 
gastrointestinal cancers and is one of the most lethal of all malignancies [1]. The burden of 
oesophageal cancer is great and the 5-year survival rate is less than 10% [2], this is due to a 
combination of factors including late presentation, associated cardiac and respiratory diseases 
and the technical difficulties of resectional surgery [3]. 
1.1.1. Historical overview: 
Recognition that tumors of the oesophagus could cause obstruction, starvation and 
death dates back to the time of Galen in the second century, when Avicenna described tumors 
of the oesophagus among the causes of difficulty in swallowing. 1,000 years ago, cancers of 
the oesophagus were being described in an area now known to be a high risk geographic 
location, modern Iran [4]. 
1.1.2. Clinical aspects: 
Oesophageal cancer occurs as one of two histological types in most patients, either 
squamous cell carcinoma (SCC) or adenocarcinoma (ADC). The vast majority (90%) of 
oesophageal cancers worldwide is squamous cell carcinoma; the remainder (10%) is 
adenocarcinoma. Dysphagia (difficulty with swallowing) is the usual first symptom, which is 
often delayed until the tumor is established and it may be associated with vomiting and 
regurgitation. The most helpful diagnostic procedures include: barium swallow 
(esophagram), which characteristically shows an irregular constriction of the lumen of the 
oesophagus and endoscopic biopsy and cytology. For treatment, if the tumor has not spread 
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too far, it may be removed with surgery or treated with radiation. The treatment plan includes 
a combination of chemotherapy, radiation therapy and surgery (multimodality therapy) [5].  
1.1.3. Risk factors: 
Epidemiological studies of oesophageal cancer have identified a variety of risk 
factors, for squamous cell carcinoma notably 1) alcohol consumption, 2) tobacco use, 3) the 
consumption of hot drinks, 4) deficiency of certain micronutrients and vitamins, 5) 
consumption of food contaminated with mycotoxins, 6) low consumption of fresh fruit and 
vegetables, and 7) infectious agents in particular human papiloma virus (HPV). The major 
risk factor for adenocarcinoma (ADC) is Barrett’s oesophagus. Barrett’s oesophagus is a 
condition in which abnormal columnar epithelial cells develop on the inner lining of the 
oesophagus caused by chronic reflux of gastric juces (gastro-osophageal reflux disease) [5,6]. 
1.1.4. Epidemiology: 
Globally the incidence of oesophageal cancere varies significantly by geographic 
regions, race and gender.  Wide variation in incidence has been reported both between 
countries and in different ethnic groups and populations. An estimated 462,000 new cases of 
OC occurred in 2002 [7]. In some areas of the world the incidence of the disease is very high, 
these areas include the so-called Asian ‘oesophageal cancer belt’, which stretches from 
eastern Turkey through the southern former Soviet Union, Iraq, North-eastern Iran, Northern 
Afghanistan and Southern Russia to Western and Northern China, Hong Kong and Japan. 
Then Southeastern Africa, France and parts of South America (Brazil, Bermoda) [8,9]. In the 
high risk area of Gonbad in Iran, world age-standardised rates were more than 200 per 
100,000 and the male/female ratio was reported as 0.8:1 [10]. As a group, Chinese are 
particularly susceptible to oesophageal cancer, with half of all OC in the world occurring 
amongst the Chinese people [11,12], the southern parts of the Taihang mountains on the 
borders of the Henan, Shansi and Hopei province in China have the highest incidence of 
 3
oesophageal squamous cell carcinoma (SCC) in the world. In the Cixian province of China, 
world age-standardised rates per 100,000 were 184 for men and 123 for women compared 
with 8.4 for English men and 3.5 for English women [13]. (80-85%) of OC cases are 
diagnosed in developing countries where it is the fourth most common cancer in men and 
most cases are SCC. Oesophageal cancer is relatively rare in whites, for example, in the 
USA, the incidence of SCC is almost six times higher in black men than in white men, while 
the incidence of adenocarcinoma (ADC) is almost four times higher in white men than in 
black men. The disease is the second most common malignancy amongst black men, 
followed by black women then white men and white women in USA [12]. Globally OC 
occurs more frequently among men than women (men are affected approximately four times 
more frequently than women) and the disease usually affects those over middle age [14,15]. 
1.1.4.1. Oesophageal cancer in Africa:                                            
High rates of oesophageal cancer have been reported in south and south-east Africa 
[16,17,18]. Certain populations of central, eastern and southern Africa display very high 
frequencies of oesophageal squamous cell carcinoma, presenting a serious health burden to 
the continent. High incidence areas in Africa include several East African countries (South 
Africa, Mozambique, Zimbabwe, Tanzania, Kenya and Uganda). In those countries there are 
a number of high incidence foci: the Transkei in South Africa, amongst the Kukuyu and near 
Lake Victoria in Kenya, amongst the Usukuma in Tanzania and amongst the Ngomi in the 
east of Zambia and Zimbabwe [19]. In South Africa the incidence of OC in certain parts such 
as Transkei and Ciskei is extremely high making it the most common malignancy amongst 
African males and the second most common cancer after cancer of the cervix in African 
females. The male to female ratio has been quoted as 1.3-1.5:1 [20,21]. 
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1.1.4.2. Oesophageal cancer in Sudan: 
For the last 5 years (2000-2005), data on cases of oesophageal cancer seen in (RICK) 
revealed that there is a clear increase of the disease in north eastern part of the country and 
that OC is the ninth most common cancer with an incidence of 5.7 %, shown in (Table 1.1). 
The disease mostly affects rural populations and nearly 200 people diagnosed each year. The 
male/female ratio reported was 1:1.3, shown in (Table 1.2). The risk of developing the 
disease increases with age. However some cases were diagnosed in people aged less than 40 
years (Table 1.3). Most of the histopatholgic examinations of the reported tumors were 
squamous cell carcinomas ranging from poorly-differentiated to well-differentiated type and 
the majority of patients presented with advanced disease.   
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Table 1.1: Number of oesophageal cancer patients registered at Radiation & Isotopes 
Center Khartoum (RICK) for the years 2000 -2004 
 
Year 2000 2001 2002 2003 2004 Total 
No. of cases 140 178 176 179 240 913 
% within top ten 15.3 19.5 19.3 19.6 26.3 100 
% of total cancers 0.88 1.12 1.1 1.13 1.5 5.7 
 
 
Table 1.2: Males / Females Distribution of oesophageal cancer registered at Radiation & 
Isotopes Center Khartoum (RICK) for the years 2000 -2004 
 
Sex Males Females Total 
No. of cases 370 543 913 
% within top ten 40.5 59.5 100 
% of  total cancers 2.3 3.4 5.8 
 
 
Table 1.3: Age distribution of oesophageal cancer patients registered at (RICK) for the years 
2000 -2004 
 
Age group 
 
Unknown  1-19 20-29 30-39 40-49 50-59 60-69 70+ Total 
Count (OC) 0 6 28 72 133 177 275 222 913 
% (OC) 0.0 .0.04 0.2 0.5 0.8 1.1 1.7 1.4 5.7 
Count (Total) 47 1501 1171 1988 2677 2801 3265 2448 15898 
% (Total) 0.3 9.4 7.4 12.5 16.8 17.6 20.5 15.4 100 
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1.1.5. Oesophageal cancer control: 
Despite the widespread use of endoscopy, significant advances in surgical techniques 
and improvement in postoperative care, chemotherapy and radiation therapy, the overall 
prognosis for patients with cancer is poor [4].  It is clear that treatment of early oesophageal 
cancers when the disease is limited to the mucosa or submucosa can yield high long-survival 
rates [5]. In high incidence areas there is a need for early diagnosis focusing on improving the 
awareness of the general public about the early symptoms. Screening programs of the general 
population in areas with high incidence of the disease have been effective in detecting early 
and curable cases. Endoscopic screening program of the general population for precancerous 
oesophageal changes has been effective in detecting early cases but the relative cost and 
benefit of this strategy has not yet been established [4,22]. Identifying a person with an 
increased risk of cancer (by screening) has the purpose of improving that person’s health 
outcomes or quality of life, through clinical management strategies to reduce risk or through 
intrinsic benefits of the information itself (better informed choice about life decisions) [23]. 
Correct diagnosis is essential using correct techniques, which is needed to confirm the 
diagnosis. Any identifiable cases discovered should be treated in the appropriate manner. The 
active involvement of the person with his/her family in treatment and follow up is of 
paramount importance. The health care system (cancer treatment center), pathology services, 
radiotherapy facility, pain relief and palliative care) should ensure that people with 
oesophageal cancer have access to appropriate standard of health care and proper follow up 
[23].  
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1.1.6. Molecular alterations in oesophageal cancer: 
Cancer is the result of an accumulation of genetic alterations that disrupt the control 
of cell growth and termination differentiation. Oesophageal squamous cell carcinoma 
develops as the result of a sequence of histopathological changes that typically involve 
oesophagitis, atrophy mild to severe dysplasia, carcinoma in situ and finally invasive cancer 
[24,25].  The possibility of genetic events underlying oesophageal tumorgenesis arose from 
observations of an occasional familial incidence or clustering of this disease and its 
association with the rare autosomal-dominant disorders [26]. A study of high-risk families in 
China suggested an autosomal-recessive inheritance influenced by environmental factors 
predisposing 4% of the population to develop the disease [27]. Following the development of 
PCR-based molecular techniques in 1980’s oesophageal tumors were analyzed for alteration 
of various oncogenes, growth factor receptors genes and tumor suppressor genes [22].  Many 
researches revealed a potential role for activation of oncogenes (epidermal growth factor EGF 
and C-myc) and inactivation of several tumor suppressor genes (p53 and p16) in the process 
of tumorgenesis [14,24,28].  
1.2. Genetic polymorphism: 
Genetic polymorphism is the occurrence in a population (or among populations) of 
several phenotypic forms associated with alleles of one gene or homologe of one 
chromosome resulting from mutation mechanisms in a gene or a chromosomal locus that 
create multiple forms (polymorphs) of that locus [29]. Genetic polymorphism is a type of 
genetic variation in which individuals with sharply distinct qualities coexist as normal 
members of a population. The three main variation types at the DNA level are, single 
nucleotide changes (now named SNPs for single nucleotide polymorphisms), insertions or 
deletions (Indels) of various lengths ranging from one to several hundred base pairs and 
variations in the number of tandem repeats (VNTR) [29].  
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1.2.1. Single nucleotide polymorphism (SNPs): 
A single nucleotide polymorphism (SNP) can be defined as a single or one base pair 
site in the human genome that is different from person to person.  This difference can be 
expressed either as a deletion, an insertion, or a substitution of a nucleotide.  Because a single 
nucleotide change occurs every 100-1000 base pairs, SNPs are the most frequently found 
type of genetic markers in the human genome [30]. Mutation at a single gene may involve 
different degrees of change in the DNA and the protein sequence. For example, a mutation 
may be just a substitution in a single base pair in the DNA molecule, such as a replacement of 
one nucleotide for another (transition or transversion) [31]. A single nucleotide change can 
affect a long stretch of DNA if it results in an insertion or deletion of a nucleotide, which is (a 
frame shift mutation) that changes all the subsequent codons in a transcript. The result of 
such a mutation could be the synthesis of only a small part of a polypeptide because of the 
introduction of a stop codon, which would result in a nonfunctional protein [31]. The major 
advantage of SNPs however, lies in the fact that they can be detected in a highly automated 
way using DNA chips. By March 2001, 2.84 million SNPs had been deposited in a public 
database, 1.65 million of which were non-redundant [32]. Mapping of SNPs was performed 
by sequence comparison with the assembled human genome sequence. In total, a map of 1.42 
million SNPs, providing an average density of one SNP every 1.91 kb, was produced by 
February 2001 [33]. As suggested by the acronym, a SNP marker is just a single base change 
in a DNA sequence, with a usual alternative of two possible nucleotides at a given position. 
For such a base position with sequence alternatives in genomic DNA to be considered as an 
SNP, it is considered that the least frequent allele should have a frequency of 1% or greater. 
Molecular markers, revealing polymorphisms at the DNA level are now key players in human 
genetics [34]. 
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1.2.2. SNPs as molecular (DNA) markers: 
Single nucleotide polymorphism is a new and very promising molecular marker 
system that offers opportunities to asses the genetic variations in certain positions in the 
human genome [34]. Depending on the type of information they provide at a single locus, 
molecular DNA markers are categorized into three main groups, firstly the bi-allelic 
dominant, such as RAPDs (random amplification of polymorphic DNA) and AFLPs 
(amplified fragment length polymorphisms), Then the bi-allelic co-dominant, such as RFLPs 
(restriction fragment length polymorphisms) and SSCPs (single strand conformation 
polymorphisms). The third group is the multi-allelic co-dominant, such as the microsatellites 
[34,35]. For SNP genotyping, there are many techniques available: 1) Direct hyperdization 
techniques, 2) Generation and separation of an allele-specific product, 3) Restriction enzyme 
cutting, 4) Single strand conformation and heteroduplex,  primer extension, 5) 
Oligonucleotide ligation assay (OLA), 6) Pyrosequencing, 7) Exonuclease detection, and 8) 
Invasive cleavage of nucleotide probes (invader assay). The recent genotyping set is the use 
of Taqman assay, based on 5’ to 3’ exonuclease removal of a quencher and fluorimetry [36].  
1.2.3. Restriction fragment length polymorphism (RFLPs):  
The restriction fragment length polymorphism is a SNP genotyping technique that 
depends on variation in the lengths of DNA fragments resulting from predictable cutting by 
restriction endonuclease enzymes [37]. RFLP is usually caused by mutation at a cutting site 
of restriction enzymes. The different fragments produced are typically detected by 
electrophoresis of digested PCR product. The first large scale effort to produce a human 
genetic map was performed mainly using RFLP markers, the best known genetic markers at 
the time [38], with the generation of PCR and the demonstration of Mendelian inheritance of 
multiple alleles, a change in strategy of RFLP was made and all the successive genetic maps 
in human were based mainly on this new type marker [39]. 
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1.2.4. Restriction Endonucleases: 
Restriction endonucleases (RE) are bacterial enzymes that cleave DNA molecules of 
any source (from inside) into short pieces in a sequence specific manner depending on the 
particular enzyme used. RE recognize specific nucleotide sequences in the DNA and then 
cleave the DNA double helix at that site. The sequence recognized by restriction enzymes is 
usually 4 to 6 base pairs in length and it is palindromic [36]. They were called restriction 
enzymes because their presence in a given bacteria restrict the growth of certain bacterial 
viruses (Bacterio phages) by cutting the DNA of those infective phages.  Restriction enzymes 
are thought to be part of the cell's defenses against invading bacterial viruses. The host 
bacteria protect their own DNA by methylation of bases at the cutting sites. Restriction 
enzymes are isolated from a wide variety of bacterial genera and now about 400 enzymes 
have been discovered. Restriction enzymes are named after the bacterium from which they 
are isolated by using the first letter of the genus, the first two letters of the species, and the 
order of discovery, for example, EcoR1 is from Escherichia Coli [40]. 
1.3. Metabolic polymorphisms and cancer risk:  
Biotransformation plays an important role in the carcinogenic activity and organ 
specificity of environmental carcinogens. Large individual variation in the biotransformation 
has been reported and polymorphisms of metabolic genes have been implicated in chemical 
exposure-related carcinogenesis [41]. Interindividual variation in susceptibility to cancer may 
partly be explained by differences in the formation and elimination of carcinogens in the 
environment. Genetic polymorphism in enzymes of carcinogen metabolism has been found to 
have the influence on the susceptibility to numerous cancers [42,43]. Nongenetic factors such 
as age, gender, smoking, alcohol and diet might influence the activity of the enzymes. 
Environmental factors may stimulate the synthesis of more enzyme protein enhancing the 
enzyme metabolic capacity, which leads to an increased serum carcinogen concentration and 
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development of cancer [44]. As a result, the metabolic conversion and excretion rate of 
carcinogen vary between individuals from extremely slow to ultrafast. By use of genotype 
analysis every individual can be classified as; poor, intermediate, extensive or an ultra rapid 
metabolizer.  It is possible that some individuals may be at increased risk for oesophageal 
cancer due to inability to metabolize or detoxify certain carcinogens or mutagens in the 
environment [42]. 
1.3.1. Polymorphisms in genes controlling alcohol metabolism: 
Several epidemiological studies have provided convincing evidence that chronic 
alcohol consumption is a strong risk factor for oesophageal cancer [43], the frequency of the 
disease among heavy alcohol drinkers is estimated to be approximately 25 times higher than 
nondrinkers. The form in which alcohol is taken is important, it is possible therefore, that 
other components of alcoholic drinks, rather than alcohol itself, causes oesophageal cancer 
[14, 44]. Although drinking alcohol is an established esophageal cancer risk factor, the 
mechanisms by which alcohol induces this high-mortality rate cancer are not clear [45].  
1.3.1.1. Alcohol metabolism: 
Ingested ethanol is absorbed slowly from the stomach during which process it may be 
subjected to oxidation as the gastrointestinal tract similar to the liver contains alcohol 
dehydrogenase (ADH), ethanol leaving the stomach is very rabidly absorbed from the upper 
small intestine across the gut mucosa and then carried to the liver by the portal vein. The vast 
majority of ethanol metabolism occurs in the liver in two phases, phase I is the oxidation of 
ethanol to acetaldehyde catalyzed by the cytosolic alcohol dehydrogenase (ADH) enzyme 
[45]. Most of the acetaldehyde generated during alcohol metabolism is oxidized in phase II to 
acetate catalyzed by the mitochondrial aldehyde dehydrogenase (ALDH2). Acetate is then 
released from the liver and metabolized by heart and muscle [46]. Both ADH and ALDH2 
enzymes are expressed at highest levels in liver, but at lower levels in other tissues. 
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Experimental studies have supported the hypothesis that ethanol per se is not carcinogenic 
but under certain conditions it could act as a co-carcinogen and/or a tumor promoter [47,48]. 
The metabolism of ethanol leads to generation of acetaldehyde and its production or 
degradation is modulated due to functional polymorphisms of the genes coding for the 
enzymes. Evidence has accumulated that acetaldehyde, which is a highly reactive molecule 
that can form adducts with proteins and nucleic acids, is predominantly responsible for 
alcohol-associated carcinogenesis [45,49]. The occurrence of genetically determined atypical 
form of ADH and ALDH2 with altered kinetic properties has been reported in many 
populations and the contribution of this polymorphism to oesophageal cancer has been 
described [50]. However the way enzyme polymorphisms influence individual cancer 
susceptibility is a new area of research [51]. The variant alleles of alcohol-metabolizing genes 
have also been studied for association with alcoholic liver disease, fetal alcohol syndrome, 
cardiovascular disease (CVD), gout, asthma and clearance of xenobiotics [52]. 
1.3.1. 2.  Phase I enzyme: Alcohol dehydrogenase (ADH): 
1.3.1. 2.1. Naming and classification of ADH:   
Liver alcohol dehydrogenase, ADH (E.C.1.1.1.1), Alcohol: NAD+ Oxidoreductase 
(also called Aldehyde reductase) is the enzyme involved in one of the rate-limiting steps in 
ethanol metabolism, the oxidation of the ethanol to acetaldehyde. ADH enzyme contains 
several homo and heterodimers formed by the association of three types of subunits, α, β and 
γ   which are governed by three separate structural loci, ADH1, ADH2 and ADH3 
respectively. They can be differentiated by their electrophoretic mobility, pH optima and Km 
for ethanol (Table 1.4) [53]. The oxidation of ethanol is mainly controlled by ADH2 locus. 
Alcohol dehydrogenase acts on primary or secondary alcohols or hemiacetals. It catalyzes the 
transfer of a hydride from the hydroxyl carbon of ethanol to NAD. ADH is a dimer of two 
subunits (80 KD), each of which contains two zinc atoms (metalloenzyme) one is in the 
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active site of the enzyme [51]. The binding of the adenosine domain is pH-dependent while 
the binding of the rest of the molecule is pH-independent. This would seem to indicate that 
the net charge of the protein would affect the speed of binding, with binding proceeding 
faster when more negative charges are present. Alcohol dehydrogenases catalyze the 
reversible oxidation of alcohols to aldehydes, acting on a wide range of substrates, from 
methanol to long-chain alcohols and sterols. [54]. 
Reaction:       An alcohol + NAD (+) = an aldehyde or ketone + NADH  
1.3.1.2.2. Genetic polymorphism of ADH:   
Humans have at least six genetic loci encoding ADH (ADH1- 6) respectively; these 
genes are located in the same region of chromosome 4 [55]. The human class I ADH genes 
lie in head to-tail array within 80 kb, in the order 5’-ADH3-ADH2- ADH1 [56]. The class I 
gene cluster is on chromosomal region 4q22-23 [57]. Single nucleotide polymorphisms in 
ADH genes give rise to enzyme variants with different amino acid residues and enzymatic 
properties. Known polymorphism occurs at two of these loci (ADH2 encoding β and ADH3 
encoding γ subunit) [58]. With ADH2 (for which there are at least three different alleles) and 
ADH3 (for which there are at least two different alleles) having greatest clinical relevance.  
Some forms of ADH2 (ADH2*2) and ADH3 (ADH3*1) are associated with a faster rate of 
metabolism of alcohol [59]. The superactive ADH2*2 allele (Arg47His) has about a 40 times 
higher Vmax than the lessactive ADH2*1. ADH2*2 is highly prevalent in more than 90% of 
Asians, but in fewer than 20% of Caucasians or Africans [58].  On the other hand the active 
ADH3*1 allele produces acetaldehyde twice as fast as that encoded by the lessactive 
ADH3*2 allele (Arg271Glu, Ile349Val) [60].  
 
Figure 1.1: Alcohol metabolizing-enzymes 
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Table 1.4: Properties of ADH in humans 
 
  
Class New 
classification 
Subunit Km ethanol Expression 
Class I 
ADH1 
ADH2 
ADH3 
 
Class II 
ADH4 
 
Class III 
ADH5 
 
Class IV 
ADH7 
 
Class V 
ADH6 
 
Class VI 
ADH8 
 
ADH1A 
ADH1B 
ADH1C 
 
 
ADH2 
 
 
ADH3 
 
 
ADH4 
 
 
ADH5 
 
 
ADH6 
 
α 
β 
γ 
 
 
п 
 
 
х 
 
 
б, µ 
 
 
- 
 
 
- 
 
4 
0.05 - 34 
0.6 - 1 
 
 
34 
 
 
1000 
 
 
20 
 
 
30 
 
 
- 
 
Livere 
Liver, lung 
Liver, stomach 
 
 
Liver, cornea 
 
 
Most tissues 
 
 
Stomach, 
oesophagus 
 
 
Liver, stomach 
 
 
Not detected in 
human 
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1.3.1.3. Phase II enzyme: Aldehyde dehydrogenase (ALDH2): 
1.3.1.3.1. Properties and tissue expression of ALDH2: 
Human liver contains two major aldehyde dehydrogenase [aldehyde: NAD+ 
oxidoreductase] isozymes, a cytosolic ALDH1 component and a mitochondrial ALDH2 
component, (Table 1.5) [61]. Mitochondrial aldehyde dehydrogenase, EC.12.1.3. is a 
tetrameric protein resbonsible for maintaining low concentration of acetaldehyde during 
ethanol oxidation. It has very low Km for acetaldehyde which makes it the most important 
isozyme for the oxidation of acetaldehyde produced from ethanol [62].  
 
 
 
 
Table 1.5: Classification of ALDH 
 
Class New classification Subunit Km ethanol 
Class I 
ALDH1 
 
 
Class II 
ALDH4 
 
Class III 
ALDH5 
 
ALDH1A 
ALDH1B 
 
 
ALDH2 
 
 
ALDH3 
 
α 
β 
 
 
п 
 
 
Х 
 
4 
0.05 - 34 
 
 
34 
 
 
1000 
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1.3.1.3.2. Genetic polymorphism of ALDH2: 
The gene for ALDH2 enzyme is located on chromosome 12q24.2 where a single base 
pair difference in exon 12 (G→A) results in the substitution of glutamine at position 487 by a 
lysine, a change that leads to a catalytically inactive enzyme variant ALDH2*212 [63]. 
Human ALDH2 deficiency is the first example of a dominantly acting mutation that alters 
turnover of the enzyme [64,65]. ALDH2*2 is the strongest genetic factor that influences the 
risk for alcohol related problems. Individuals possessing the abnormal ALDH2*2 allele show 
alcohol related sensitivity response (e.g. facial flushing) and have the tendency not to have 
habitual drinkers, they apparently suffer less from alcoholism and alcohol related disorders 
[66]. This mutant allele, which is found only in Orientals at a frequency of approximately 
50%, was reported to be a risk factor for upper aerodigestive tract, oro-pharynx and 
oesophageal cancers [67]. 
  
1.3.2. Genetic polymorphisms in xenobiotic- metabolizing enzymes: 
The basic purpose of metabolism of foreign compounds in the human body is to make 
them more water soluble and thus more readily excreted in urine or bile. Biotransformation 
enzymes are present in most epithelial tissues of the human gastrointestinal tract [68]. Their 
presumptive function is to protect tissues against toxic or carcinogenic compounds, which 
enter the body as either food additives or drugs [69]. Almost all carcinogens in the 
environment are metabolically oxidized by phase I enzymes, cytochrome P450s (CYPs) into 
genotoxic compounds which could react with DNA forming adduct and subsequent DNA 
mutation. Excretion of these reactive metabolites requires action by phase II enzymes, 
glutathione S-transferases (GSTs), sulfotransferases (SULTs) or N-acetyltrasferases (NATs) 
[70,71]. The concentration of the ultimate carcinogen that will react with DNA, is determined 
by the rate of activation and detoxification. Functional polymorphisms in genes coding for 
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enzymes involved in xenobiotic-metabolism have been extensively studied in relation to 
different types of cancers and have the influence on the susceptibility to numerous cancers 
[42,72]. The combination of the high risk genotypes is associated with an increased risk of 
cancer development, the genotypes with high phase I enzyme activity and low phase II 
enzyme levels are considered to pose a high risk cancer development [73]. 
1.3.2.1. Phase I metabolizing enzymes: Cytochrome P450s 
Cytochrome P450 enzyme system, EC (1.14.14.1) constitutes a large superfamily of 
haem-thiolate proteins important in phase I activation reactions of the biotransformation [74]. 
They were first discovered in 1955 in rat liver microsomes and are characterized by an 
intense spectrophotometric absorption band at 450 nm in the presence of carbon monoxide 
(P450= pigment 450) [40]. P450s are widely distributed across species and they are involved 
in the metabolism of a wide range of both endogenous and exogenous compounds (drugs, 
dietary constituents and endogenous chemicals). In mammals all CYPs are membrane bound 
and are found in the endoplasmic reticulum but few of them are localized primarily in the 
mitochondria. The P450s in the endoplasmic reticulum are all nonspecific mixed-function 
oxidases or monoxygenases that interact with and receive electrons from a single flavoprotein 
NADPH-P450 reductase; CYP P450s are induced or inhibited by many chemicals and 
hormones. In humans P450 enzymes are found in all tissues but mainly in liver, intestine, 
skin and lungs [40].   
1.3.2.1.1. Classification and typical substrates of CYP450s:   
Today CYP 450 enzymes are categorized into families and subfamilies depending on 
their amino acid sequence specificity.  Members of a family are at least 40% identical. Within 
a family enzymes with greater than 55% sequence homology are included in the same 
subfamily [74]. The human genome encodes fifty seven cytochrome P450 proteins, fifteen 
involved in the metabolism of xenobiotic chemicals (drugs and carcinogens), fourteen 
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primarily involved in the metabolism of sterols (including bile acids), four that oxidize fat-
soluble vitamins and nine involved in the metabolism of fatty acids and eicosanoids. 
Substrates (either endobiotic or xenobiotic) are essentially unknown for the remaining fifteen 
of the fifty seven P450s [75].  
1.3.2.1.2. Major groups of CYP450s (Subfamily 3A): 
CYPs play important roles in the oxidative metabolism of several pro-carcinogens to 
their ultimate reactive forms. In humans the main P450s involved in carcinogen activation 
appear to be CYP1, 2, and 3 families. A number of these enzymes are polymorphically 
expressed, resulting in different metabolic activities [76]. CYP3A isozymes constitute the 
largest portion of cytochrome P450 protein in the liver and small intestine. CYP3A enzymes 
are the most important subfamily of P450s in xenobiotic metabolism and are responsible for 
the biotransformation of 50-60% of all currently known drugs. There are four members of the 
subfamily 3A (3A4, 3A5, 3A7, 3A43). The expression and activity of isoforms of CYP3A4 
and CYP3A5 show wide inter-individual variation, influencing adverse toxic effects, disease 
susceptibility and carcinogenesis [77].  
1.3.2.1.3. Genetic polymorphism of CYP3A5: 
CYP3A5 may represent up to 50% of total CYP3A in individuals expressing the 
protein [78]. A range of P450 enzymes are expressed in the human oesophageal mucosa 
indicating that this tissue has the capacity to activate DNA binding chemical carcinogens. 
CYP3A5 is the major cytochrome enzyme expressed in oesophageal mucosa, it metabolizes 
many potentially carcinogenic compounds. CYP3A5 is polymorphically expressed with six 
variant alleles that appear to have a functional effect on the activity of the enzyme [79]. The 
wild type allele CYP3A5*1 (6986A) produces a correctly spliced transcript that correlates 
with high CYP3A5 activity [80]. An intronic SNP that affects splicing of the CYP3A5 
transcript produces a nonfunctional allele CYP3A5*3. This SNP, 6986G in intron 3 creates a 
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cryptic splice site leading to the inclusion of a novel exon, and ultimatey a premature stop 
codon [81]. 
1.3.2.2. Phase II metabolizing enzymes: Conjugating enzymes:  
In phase II reactions of the biotransformation the active hydroxylated derivatives of 
phase I are conjugated with molecules such as glutathione, sulfate or glucouronic acid. This 
renders them even more water-soluble to be excreted in the urine or bile [40]. Phase II 
reaction is mostly associated with detoxification. Individuals with a decreased rate of 
detoxification i.e., lacking the enzyme gene, have a slightly higher level of carcinogen in 
blood or some tissues.  In addition, the genotype itself (the null- genotype) may also 
influence the type of mutations in other genes (e.g. tumor suppressor genes). Important phase 
II enzymes are glutathione S-transferases (GSTs), sulfotransferases (SULTs) and N-
acetyltrasferases (NATs) [71]. 
1.3.2.2. 1. Glutathione S-transferases (GSTs): 
Glutathione S-transferases, GSTs (EC: 2.5.1.18) are a supergene family of enzymes 
involved in phase II reaction of the biotransformation, they play an important role in 
prevention of cancer by detoxifing (deactivating) numerous potential toxins [82]. GSTs 
catalyze the conjugation of endogenous reduced glutathione (γ glytamylcystenyl-glycine) to a 
wide variety of electrophilic lipid-soluble compounds, resulting in less reactive and more 
readily excreted glutathione conjugates. As the result of further action by peptidases and 
transferases to remove glutamate and glycine residues and subsequent acetylation of the 
cysteine, the glutathione conjugate can be degraded to a mercapturic acid and excreted in the 
urine [83].  
1.3.2.2.1.1. Naming and classification of GSTs: 
based on nucleotide homology, biochemical and immunologic criteria mammalian 
soluble GSTs are classified into four main classes; GST alpha (α), GST mu (µ), GST theta 
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(ŧ), GST pi (π) each class consisting of several isoenzymes with a partly overlapping substrate 
specificity (Table 1.6) [84]. A new class zeta (ζ) has been identified recently in humans [85] 
and a sigma class (θ) GST has been described in certain invertebrate species and rats [86]. 
1.3.2.2.1.2. Properties and tissue expression of GSTs: 
Human (hGSTs) are cytosolic homodimeric proteins (45-55 kDa), that are widely 
expressed in human epithelial tissues including gastrointestinal tract [82]. The GSTs show 
absolute substrate specificity for glutathione. Substrates of GST-catalyzed reactions include 
activated carcinogen metabolites, such as polycyclic aromatic hydrocarbons, epoxide, 
pharmacological drugs, chemotherapeutic agents and free radicals generated during oxidative 
stress [87]. GSTs also modulate the induction of certain proteins involved in DNA repair 
[82]. Distinct from their catalytic role and maintainance of cellular genomic integrity, GSTs 
bind a number of hydrophobic compounds including, heme, bilirubin and steroids. They may 
also function as intracellular ligand storage proteins [88]. GSTs make a significant 
contribution to the protection of the cell from a variety of xenobiotic and endogenous 
challenges playing an important role as a defense mechanism against cancer. GSTs are 
commonly described as detoxification enzymes. However, certain GSTs particularly GSTT1 
appear to play role in the activation of certain xenobiotics, including some alkane and alkene 
procarcinogens [89]. GSTs are inducible enzymes and they are affected by developmental, 
sex and tissue specific factors as well as a number of xenobiotic inducing agents mediated by 
several transcriptional mechanisms.  Recent studies have shown elevated levels of GST 
expression in tumors that are refractory to treatment [91]. There is evidence to suggest that 
GSTs are involved in the metabolism of chemotherapeutic agents and the resistance to 
therapeutic drugs [91]. 
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1.3.2.2.1.3. GSTM1 and GSTT1 null genotypes: 
GSTs enzymes are polymorphic and have ethnic-dependent polymorphism 
frequencies. They are present in relatively large amounts in the epithelial tissues of the 
human gastrointestinal tract [92,93]. Both GSTM1 and GSTT1 are expressed in oesophageal 
mucosa and are involved in the detoxification of reactive epoxide intermediates generated 
from the activation of polycyclic aromatic hydrocarbons and other mutagens by cytochrome 
P450 enzymes. Homozygous deletions of GSTM1 and GSTT1 genes are commonly found 
and result in lack of enzyme activity (Table 1.6) [94]. Five Mu class genes (M1-M5) on 
chromosome 1p13.3 have been identified.  The known substrates for GSTM1 are the ultimate 
carcinogenic forms of reactive epoxide, arene oxides and aflatoxin B1 [95]. Large ethnic 
variation in the frequencies of the GSTM1 alleles has been observed. 20% to 50% of 
individuals do not express GSTM1 due to a gene deletion known as the GSTM1*0, or null 
allele [96]. Cells from GSTM1 null individuals are more susceptible to DNA damage caused 
by certain GSTM1 substrates [97].  The percentage of individuals with the null genotype is 
higher in Caucasian and Asian populations (50%) than it is among people of African descent 
[98]. On the other hand the GSTT1 gene located on chromosome 22q11.2 encoded the 
GSTT1 enzyme, substrates of which include chemicals with wide industrial use such as 
methyl chloride (a methylating agent), methyl bromide (a soil fumignant), ethylene oxide 
(used for sterlization) and dichloromethane (a solvent) [99]. The GSTT1 null genotype 
exhibits population frequencies that depend on ethnicity [100,101].  Homozygous deletions 
of the gene were recorded in 24% to 38% of people from African origin [102]. The GSTM1 
and GSTT1 gene polymorphisms could be important in human carcinogenesis and seem to be 
associated with increased risk of certain cancers [103], it has been linked to lung, 
nasopharynx, breast, uortheral, prostate cancer, lymphocytic leukemia and squamous 
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displasia of the oesophagus [104,105]. An additive effect of the combination GSTM1 
null/GSTT1 null has been observed for certain types of cancers [106]. 
 
 
 Table 1.6: Classification and properties of glutathione s-transferases (GSTs) 
 
Gene GSTM1 GSTM3 GSTPi GSTT1 
Chromosome 1q13.3 1q13.3 11q13.3 22q11.23 
Length of gene (kb) 5.92 4.59 2.84 8.9 
Number of exons 8 9 7 5 
Polymorphism Deletion 3 bp deletion 
 in intron 6 
A313G 
(ILe105Val) 
Deletion 
Enzyme activity Null Uncertain Reduced Null 
Expression Liver, kidney, adrenal Lung, testis, brain lung Liver, kidney 
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1.3.2.2. 2. Sulfortransferases (SULTs): 
Sulfonate conjugation is an important phase II pathway in the biotransformation of 
numerous endogenous and exogenous compounds [107]. The reaction is catalyzed by 
sulfotransferases (SULTs) a superfamily of multifunctional enzymes. Sulfotransferases 
transfer the sulph moiety (sulfuryl group) from the cofactor 5-phosphoadenosine-3-
phosphosulfate (PAPs) to nucleophillic group (hydroxyl or amino functional group) of an 
acceptor substrate; the products are adenosine 3, 5- diphosphate (PAP) and a sulfuric acid 
ester, respectively [108].  Mammalian SULTs are all cytosolic proteins that use a broad array 
of hormones, neurotransmitters, drugs and carcinogens as substrates [109,110]. Sulfonation is 
generally considered as a detoxification mechanism that generates more water-soluble and 
often less toxic metabolites. However, conjugation of certain compounds such as benzylic, 
allylic alcohols and aromatic hydroxylamines produce short-lived electrophiles that react with 
DNA forming adducts [111,112]. A large number (>100) of procarcinogens are known that 
can be activated by SULTs [113]. 
1.3.2.2. 2.2.  Location and typical substrates of SULTs: 
On the basis of amino acid sequence identity and substrate specificity human SULT 
enzyme family can be divided into two subfamilies, phenol SULTs (family1) and hydroxy 
steroid SULTs (family2). Phenol SULTs are soluble (usually cytosolic) enzymes that 
metabolize small molecules including various hormones and numerous xenobiotics while 
hydroxyl steroid SULTs are localized in the Golgi apparatus and comprises mainly 
membrane-bound forms, they sulfonate macromolecular endogenous structures and they have 
no xenobiotic-metabolizing activities [111.114,115]. All soluble SULTs studied are members 
of a single gene/enzyme superfamily [116]. A systematic nomenclature, similar to that of the 
cytochrome P450s is in preparation and is not yet finalized, but it is already widely used for 
human SULTs.  [117]. 
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1.3.2.2. 2.3.  Major groups of SULTs (SULT1A family):  
Most of the human SULTs exist as homodimers and the monomeric subunits consist 
of 284 to 365 amino acid residues, no posttranslational modifications have been reported 
[114]. Eleven distinct xenobiotic-metabolizing sulfotransferases have been identified in 
humans encoded by ten SULT genes; they are all soluble cytosolic proteins that differ in 
tissue distribution and substrate specificity [113,118]. Three SULT1A proteins occur in 
human tissues, 1A1, 1A2 and 1A3, showing the same number of amino acid residues (295) 
and 93% to 96%  sequence identity but differ in substrate specificity and regulation 
[109,119,120]. 
1.3.2.2. 2.4. Genetic polymorphism of SULT1A1:  
All three SULT1A genes are located on chromosomae 16p11.2–12.1 [120,121]. 
SULT1A1 is one of the most important members of human SULTs due to its extensive tissue 
distribution and highest expression level, SULT1A1 appears to be the principal SULT form 
involved in the detoxification of most phenolic xenobiotic as well as activation of several 
procarcinogens such as hydroxyl arylamines, heterocyclic amines and polycyclic aromatic 
hydrocarbons (PAHs) showing broad substrate specificity [122]. Single nucleotide 
polymorphisms (SNPs) have been detected in all of the ten human SULT genes [123,124]. 
The inherited differences in the enzymatic activity of SULTs are likely to influence the 
individual\s risk for cancer [125,126]. Studies have demonstrated a large individual variation 
in the activity of SULT1A1, which could be explained by the newly identified common 
single nucleotide polymorphism in (G638A) transition in the coding region (exon 7) of the 
SULT1A1 gene (referd to as SULT1A1*2 allele). It results in (Arg213His) substitution 
associated with reduced enzyme activity and thermal stability compared with that of the 
normal SULT1A1*1 allele [107,123,124.125]. The Arg213His polymorphism in SULT1A1 
has a strong influence on the level of enzyme protein and activity in platelets [122]. An 
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individual homozygote for the SULT1A1*2 allele had only about 15% of the SULT activity 
in platelets of those with other genotypes [117]. This mutant allele occurs in relatively high 
but various frequencies in different ethnic populations, it was reported to be about 30%-35%, 
in Caucasians and about 27% in Africans and African-Americans [111.118]. The importance 
of SULT1A1 in biotransformation of carcinogens suggests that this polymorphic enzyme 
activity may have the potential to influence individual susceptibility to chemical 
carcinogenesis [119]. Several studies have shown that SULT1A1 polymorphisms may play 
some role in the development of cancers [120,127]. 
1.4. The role of the environment in (OC) development: 
Eighty to ninty persent of all human cancer is caused by external (smoking, lifestyle, 
diet, occupation) rather than inherited factors. There are cancers in which environmental 
factors are of primary importance and heredity seems to play no part in causation e.g. 
industrial cancers. However in the majority of human cancers there is no clear-cut mode of 
inheritance nor is there any clearly defined environmental cause. The nature, prevalence and 
magnitude of exposure and predisposition, however, vary between different populations. 
Oesophageal cancer like other human cancers is thought to arise as multi-step process 
modulated by both genetic and environmental risk factors but not much is known about the 
environmental carcinogens involved in the development of oesophageal cancer and the 
environmental factors are still poorly defined [26].  
1.4.1. Environmental risk factors: 
Oesophageal cancer shows striking geographical variations in incidence. There are 
high-risk and low-risk areas that may reflect the involvement of environmental risk factors. 
Tobacco and alcohol play a major role in the development of oesophageal cancer in Western 
countries. The consumption of hot drinks, such as hot tea is also considered as an important 
risk factor. Various studies involving many different population groups have demonstrated an 
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increased risk of oesophageal cancer associated with a diet deficient in vegetables, fruits and 
oligoelements. High levels of silica fragments were detected in the diet in the areas of highest 
oesophageal cancer incidence in Northern China, Transkei in South Africa and Iran 
[128,129,130]. Several infectious agents especially the human papilloma virus (HPV) have 
been implicated in oesophageal cancer [22].  
1.4.2. Human Papilloma Virus (HPV) and oesophageal cancer: 
Human Papiloma virus (HPV) has been implicated as a potential cause of oesophageal 
cancer in the Lixian region of China, where there is a high incidence of the disease [5]. The 
presence of HPV DNA has also been demonstrated in oesophageal lesions of squamous cell 
cancer in Australia, which has a low incidence of the disease [131, 26], although it would 
appear that integrated HPV DNA is not globally consistently associated with oesophageal 
cancer, approximately 50% of cancers harbour the virus in high risk areas such as China and 
South Africa [132], but the prevalence is much lower in Japan, Australia and France. How 
HPV infection may contribute to oesophageal carcinogenesis is unknown. There are 60 
different HPV types associated with oesophageal cancer, the majority of them was identified 
as HPV16 [133]. 
1.5. Gene-environment interaction in terms of oesophageal cancer: 
The unique epidemiological feature of oesophageal cancer distinguishes it from all 
other malignancies. The striking variations in geographic distribution of oesophgeal cancer 
reflect exposure to specific environmental factors but not much is known about the 
environmental carcinogens involved in the development of the disease and the inherited 
susceptibility is not belived to account for the majority of cases. Oesophageal tumergenesis is 
a multistage process modulated by the interaction of both genetic and environmental risk 
factors [44]. 
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1.6. Rationale: 
Cancer is now a major health problem throughout the world. Each year it is estimated 
to affect at least nine million people and kills five million. At present, it accounts for about 
one-tenth of all deaths worldwide. However, there has been a general lack of published 
reports on the exact magnitude of the problem in many countries including Sudan [3], where 
reliable data on cancer are scares and there is a need for establishment of population-based 
cancer registries. Recently it has been observed that oesophageal cancer is a significant health 
problem in certain districts of the northeastern part of the country. In view of the scarcity of 
precise data there is an urgent need for promoting epidemiological studies on oesophageal 
cancer in this region, to document the accurate magnitude of this problem and to evaluate the 
influence of geographic, ethnic and socioeconomic factors. Future strategies in the treatment 
and prevention of oesophageal cancer are expected to be based on advances in the 
understanding of the biochemistry and molecular biology of the disease [23]. The study of 
blood samples and biopsy material from malignant tissue offers the opportunity that tumor 
markers or genetic abnormalities may be identified, which may lead to greater refinement in 
selecting patients at risk, as well as providing insight into carcinogenesis. Genetic 
epidemiology is concerned with identifying genes that can increase a person’s risk of 
developing a certain disease and understanding the contribution such genes make to disease, 
perhaps in combination with environmental risk factors. The inclusion of the genetic analysis 
of the polymorphisms in the epidemiology of cancer is of particular interest because it allows 
the identification of subpopulations of people with increased susceptibility to cancer induced 
by environmental carcinogens. It is also able to establish the tolerable limits of exposure to 
certain agents and allows the establishment of differentiated guidelines to be followed and 
diagnosis in function of the genotypes of risk. With a view of developing diagnostic markers 
or potential targets for new therapy, a PCR-based genotyping method, restriction fragment 
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length polymorphism (RFLP) was used in this study to correlate genetic testing with well-
defined epidemiological criteria that may lead to precise identification of the factors that 
underlie oesophageal tumorgenesis in Sudanese people. Such baseline data is essential for 
monitoring the progress of future intervention programs.  
1.7. Objectives: 
The general aim of this study was to characterize genetic differences in carcinogen 
metabolizing genes in Sudanese oesophageal cancer patients compared to healthy controls 
using single nucleotide polymorphisms (SNPs) as molecular markers and to investigate the 
correlation between these polymorphisms and the risk of oesophageal cancer in Sudan.  
The specific objectives were, to: 
1- Determine the role of genetic polymorphisms in alcohol-metabolizing enzymes in the 
development of oesophageal cancer in Sudan. 
2- Assess the impact of polymorphisms of xenobiotic-metabolizing enzymes on susceptibility 
to oesophageal cancer among Sudanese. 
3- Investigate gene-environment interactions in polymorphism of CYP3A5 and SULT1A1 
enzymes (alone or in combination) in terms of occurrence of oesophageal cancer in Sudan. 
  4- Investigate the association between the GSTM1 and GSTT1 null-genotypes and 
oesophageal cancer risk using PCR-based method. 
5- Determine allele frequencies of ADH, ALDH2, GSTM1 GSTT1, CYP3A5 and SULT1A1 
in Sudanese. 
 
 
 
 
 29
Materials and methods 
2.1. Study design: 
This is a prospective hospital-based case-control study conducted to characterize 
genetic polymorphisms and other molecular markers and their possible role in finding factors 
leading to oesophageal cancer in Sudan. 
 
2.2. Study centers:  
  Khartoum Teaching Hospital and National Center for Gastrointestinal and Liver 
Diseases, Ibn Sina Hospital in Khartoum. 
 
2.3. Research ethics: 
Informed consent was obtained from all patients and controls to participate in this 
study. The study was approved by the board of Medical Research of Faculty of Medicine, 
University of Khartoum.  
 
2.4. Study population: 
A total of 134 oesophageal cancer patients and 233 healthy controls were invited to 
participate in genetic testing for mutations in carcinogen-metabolizing genes.  
I. Patients:  
One hundred and thirty four oesophageal cancer patients (69 male and 65 female) 
attending the respective hospitals between the periods (2001-2005) were included. The 
criteria for including patients in this study were the following: 
- They must be diagnosed clinically and confirmed histologically as having 
oesophageal cancer. 
- Consent to participate in genetic testing. 
-  Patients who received irradiation or chemotherapy were excluded from this study 
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and all those who withdrew their consent were also excluded. 
II. Controls:  
  Two hundred and thirty three healthy Sudanese volunteers (112 male and 121 female) 
were included after informed verbal consent. They were matched to the patients with respect 
to their ethnicity and gender distripution. Those with any family history of malignancy were 
excluded from the control group.   
2.5. Sampling: 
 I. A (5ml) sample of peripheral venous blood was collected from patients and controls in 
closed tubes containing EDTA as an anti-coagulant and stored at – 20 ºC until use. 
II. Oesophageal biopsies were collected from all patients and were kept frozen immediately 
after removal and then stored in liquid nitrogen until use. 
 
2.6. Data collection: 
Sources of data included, clinical examination (done by the physician in the 
respective hospitals), personal interview, a questionnaire and laboratory investigations. 
The questionnaire:  
A simple questionnaire was designed and used for each patient; it included complete 
demographic characteristics, present and family history of cancer, person’s habits and 
medical history. Another questionnaire was designed for control subjects including same 
questions. 
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2.7. Laboratory methods:   
2.7.1.   DNA Extraction: 
The extraction of the DNA was either from the fresh tissue, blood or the blood that 
was stored in - 20°C. 
2.7.1.1. DNA extraction from blood:  
Genomic DNA was extracted from peripheral blood lymphocytes of patients and 
controls using three different methods, two of them are routinely used in the laboratory 
(standard phenol chloroform extraction and the salting out method) and the Qiagen DNA 
isolation kits. 
I. Parazer’s rabid method: 
  This method is for 5 ml fresh or frozen blood, it is suitable for PCR reactions and has 
a good DNA yield (about 250 mg from 5ml whole blood) and good 260/280 absorbance 
ratios. 5 ml fresh or frosen blood were thawed rapidly at 37°C, mixed with 50 ml cell lysis 
buffer (109.5 g Sucrose, 5 ml 1M MgCl2,10 ml 1M, Tris, 10 ml Triton X100 H2O up to 1L) 
and was shaken and incubated for 15 mins on ice. The mixture was then centrifuged at 9000 
rpm for 10min at 4°C. The supernatant was decanted and the pellet was resuspended in 10 ml 
washing buffer (0.58 g NaCl, 3.72 g EDTA, H2O up to 1L), shaken and centrifuged at 9000 
rpm for 10 min at 4°C, then the supernatant was siphoned off. To the almost white pellet the 
following solutions were then added in the respective order, Sarkosyl solution (20% Na 
laurylsarcosinate, Sigma L5125) 350 µl, ammonium acetate solution (7.5 M) 250 µl, 
guanidine solution 3.5 ml (6.0M) and then 125 µl (10mg/ml) proteinase K. The mixture was 
incubated at 60°C until clear (10-15min) and then cooled to 0°C on ice. Adding 10 ml ice-
cold ethanol precipitated the DNA. After 1 hour the DNA spooled off with a hooked glass 
rod. The extracted DNA was dissolved in 1ml TE buffer (Tris HCL 10 mM, EDTA 1 mM at 
pH 8.0), kept for 1 hour at 37°C, labeled and was stored at -20°C. 
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II. Salting out method:  
Purification of DNA from frozen blood (for 5 ml sample). The blood was thawed at 
room temperature and then transferred to a sterile polypropylene tubes then it  was diluted 
with 2 volume of PBS (1 mM KH2PO4, 154 mM NaCl, 5.6 mM Na2HPO4, pH 7.4) mixed by 
inverting the tubes and centrifuged at 2200 g for 10 min.  The supernatant was poured off and 
the pellet (reddish) was resuspended in 25 mL of Sucrose Triton X-100 Lysing Buffer (1 M 
Tris-HCl 10 ml, 1 M MgCl2 5 ml Triton X-100 10 ml Made up to 1 liter with distilled water).  
Sucrose was added just before use i.e. (11 g/100 mL). The mixture was vortexed and then 
placed on ice for 5 minutes.  The mixture was spun for 5 minutes at 2200 g (2300 rpm in 
TH.4 rotor) and the supernatant was poured off. The pellet (pinkish or white) was 
resuspended in 3 mL of T20E5 (0.6X volume of original blood). 10% SDS was added to a 
final concentration of 1% (200 µL) then Protienase K was added (10 mg/mL) to a final 
concentration of 250 µg/mL (75 µL). The mixture was mixed by inversion after adding each 
solution then the samples were incupated at 45°C overnight. 1 mL of saturated NaCl was 
added to each sample and mixed vigorously for 15 seconds then it was spun for 30 minutes at 
2400 g. A white pellet was formed which consisted of protein precipitated by salt, the 
supernatant that contained the DNA was transferred to a new tube and precipitation of DNA 
was achieved by adding two volumes of absolute alcohol kept at room temperature. The 
solution was agitated gently and the DNA was spooled off and transfered to eppendorf tube.  
The DNA was washed in 70% ice-cold alcohol (1 mL), air dried and was dissolved in the 
appropriate volume of TE (100-250 µL) and stored at 4 degrees overnight to dissolve.  
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III. Blood DNA extraction (FlexGene DNA isolation kit):  
Genomic DNA was isolated using the protocol for isolation of DNA from 100-500 µL 
whol blood. 750 µL of the lysis buffer were pipetted into a 1.5 ml centrifuge tube. 300 µL 
whole blood was added mixed by invertiong the tube 5 times and the mixture was centrifuged 
for 20 second at 10,000 Xg in a fixed-angle rotor.The supernatant was discarded and the tube 
was left inverted on a clean piece of paper for 2 minutes. To the pellet remained 150 µL of 
the denaturation buffer/1.5 µL GIAGEN Protease were added, the tube was closed and vortex 
immediately until the pellet was completely homogenized. The tube was centrifuged (3-5 
seconds) and was placed in a water bath (65ºC for 5 minutes). The DNA was precipitated by 
the addition of 150 µL isopropanol (100%), mixing and centrifugation for 3 minutes at 
10,000 Xg. The supernantant was discarded and the DNA pellet was washed with 70% 
ethanol and air dried (for at least 5 minutes). The DNA was resuspended in 200 µL hydration 
buffer and was dissolved by incubation for 10 minutes at 65ºC in a water bath. 
3.7.1.2. DNA extraction from tissue: 
Oesophageal biopsy or resection specimens were used for genomic DNA extraction.  
The process involved four stages, preparation of cells, cell lysis and digestion, DNA 
extraction and DNA purification. Genomic DNA was extracted from fresh-frozen biopsy and 
resection specimens. From 1gram mammalian cells, 2 mg DNA can be expected. The tissue 
was rapidly frozen in liquid nitrogen and then crushed with a sterile blade to a fine powder. 
The powdered tissue was suspended in 200 µl digestion buffer (100 ml of, 100 mM NaCl 2 
ml, 10 mM Tris.Cl 1 ml,  25 mM EDTA 5 ml) 1.2 ml per 100 mg tissue and incubated with 
shaking at 50°C for 12 to 18 hour in tightly capped tubes. 2 µl of 10 µg/ml DNase –free 
RNase were added and the mixture was kept at 50°C for 1 hour.  An equal volume of 
phenol/chloroform/ isoamyl alcohol (200 µl) was added, shaked and centrifuged at 4°C for 10 
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min at 13000 rpm. The aqueous supernatant layer was taken to a new tube and 100 µl of 
7.5M ammonium acetate, then 200 µl of 96% ethanol were added, the DNA was immediately 
preciptated, it was shaken and centrifuged for 2 min. The pellet was rinsed with 70% ethanol 
and left to dry. The DNA was resuspended in 500 µl TE buffer until it dissolved. The tubes 
were labeled and stored at - 20°C.  
2.7.1.3. Electrophoresis of the extracted DNA in agarose gel: 
DNA is detected by electrophoresis on gels and stained with ethidium bromide, which 
has an intense fluorescence excited by ultra-violet radiation when it complexes with nucleic 
acids. 2-3µl of the extracted DNA was mixed with 2-3 µl of loading buffer. Two µl DNA 
were loaded on the gel (the gel was prepared by mixing 1.5 gm agarose, 100 ml 1X TBE 
buffer, 4 µl ethidium bromide 10 mg/ml). Molecular weight DNA marker (HindIIECoR1) 
was run on every gel. The gel was run in 1X TBE running buffer and electrophoresis was 
carried out at 145 volts for 5 min then the gel was viewed under UV light and photographed.  
 3.7.1.4. Spectrophotometric determination of DNA concentration and purity:  
The DNA yield was determined spectrophotometrically by measuring the absorbance 
at 260 and 280nm. The DNA was diluted 1: 50 with distilled water (10 µ DNA+ 490 µl H2O). 
Reading of DNA concentration was done at 260 and 280nm using (Beckman 
spectrophotometer, USA), water was used as a blank.   
1A260 double-stranded DNA = 50 µg/mL 
1A260 single stranded DNA = 37 µg/mL 
Concentration = A260 X dilution factor X conversion factor 
Purity A260/A280: 
An A260/A280 ratio greater than 1.8 indicates highly purified preparations of DNA and RNA 
respectively. Contaminants that absorb at 280 nm (e.g a protein) will lower the ratio. 
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A working solution of DNA (100 ng/µl) was prepared from each sample and kept on 4˚C. 
The stock DNA was stored in -20˚C. 
 
2.7.2. Primer design and PCR Analysis: 
2.7.2. 1. Primer design: 
Nine pairs of primers were designed using the published data for sequences to amplify 
different DNA fragments of ADH2 exon3, ADH2 exon9, ADH3 exon8, ALDH2 exon12, 
CYP3A5 intron 3, GSTM1, GSTT1, HAS and SULT1A1 exon 7 genes. Design of all primers 
was carried out in our lab and they were synthesized in a Beckman 1000A DNA synthesizer 
at the Department of Medical Biochemistry, Medical School, University of  Cape Town, 
South Africa. 
The annealing temperature of each primer was calculated according to the rule: 
Tm = 2(A+T) + 4(G+C) – 5 
The optimal amount of each primer was calculated using the formula: 
Molecular Weight of the primer = Molecular Weight of one base X No. nucleotides (length of 
the primer) 
 (Length of the primer = 3X No. of codons). 
2.7.2.2. Standard PCR reaction: 
The experiment consists of the experimental DNA, a positive control and a negative 
control.  In a 0.5 ml PCR tube the following solutions were placed in a total volume of 25 
µl or 50 µl: 
- 10X Taq buffer (final concentration 200 µl 1X) 
- 2.5 mM 4dNTP stock (final concentration 200 µmol) 
- 10 µmol/µl primer F (final concentration 0.5 µmol) 
- 10 µmol/µl primer R (final concentration o.5 µmol) 
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- 100 ng of genomic DNA template. 
- MgCl2 (final concentration 1.5µm)  
- H2O (up to the total volume used) 
- 1u Taq. Polymerase (Gotaq polymerase 5u/µl, Promega/MADISON WI USA). 
 For DNA amplification PCR machines (PCRexpress, UK) and (GeneAmp PCR system, 
Applied Biosystem) were used. The Gene name, primer sequence, annealing temperature 
and length of the amplified region are shown in (Table 2.1). The PCR programs for the 
different genes are shown in (Table 2.2). 
2.7.2.3. Electrophoresis of PCR products: 
To confirm the presence of amplifable DNA in the samples, the specificity of PCR 
was analyzed by evaluating the production of the target fragment by gel electrophoresis of 5 
µl PCR products on 2.0% (1 g agarose, 50 ml 1XTBE, 4 µl ethidium bromide 10 mg/ml) 
agarose gel stained with ethidium bromide and visualized with an ultraviolet transluminator.  
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Table 2.1: Gene name, primer sequence, annealing temperature and PCR product length 
 
 
 
Gene Primer sequence AT 
(°C) 
Leng. PCR 
(bp)  
 
ADH2 exon 3 
 
 
ADH2 exon 9 
 
 
ADH3 exon 8 
 
 
ALDH2 exon 12 
 
 
Cyt 3A5*3 
 
 
SLUT 1A1 
 
 
GSTT1 
 
 
GSTM1 
 
 
HAS 
 
Fwd 5’- AATCTTTTCTGAATCTGAACAG - 3’ 
 Rev 5’- GAAGGGGGGTCA CCAGGTTGC - 3’ 
 
Fwd. 5’- TGGACTCTCACAACAAGCATGT-3’ 
Rev 5’-TTGATAACATCTCTGAAGAGCTGA- 3’ 
 
Fwd 5’-CTTTAAGAGTAAAGAATCTGTCC-3’  
Rev  5’-ACCTCTTTCCAGAGCGAAGCAG- 3’ 
 
Fwd 5’-CCACACTCACAGTTTTCTCTT-3’  
Rev  5’-CCCTTTGGTGGCTAGAAGATG – 3’ 
 
Fwd  5’-CATCAGTTAGTAGACAGATGA-3’  
Rev 5’-GGTCCAAACAGGGAAGAAATA-3’ 
 
Fwd 5’-GTTGCCTCTGCAGGGTCTGGAGAG-3’  
Rev 5’-CCC AAA CCC CCG TAC TGG CCA GCA CCC - 3’ 
 
Fwd 5’-TTC CTT ACT GGT CCT CAC ATC TC-3’  
Rev 5’-TCA CCG GAT CAT GGC CAG CA- 3’ 
 
Fwd 5’-GAA CTC CCC TGA AAA GCT AAA GC-3’  
Rev 5’-GTT GGG CTC AAA TAT ACG GTG G- 3’  
 
Fwd 5’GCC CTC TGC TAA CAA GTC CTA-3’  
Rev 5’-GCC CTA AAA AGA AAA TCC CCA ATC- 3’ 
 
55 
 
54 
 
 
53 
 
 
52 
 
 
55 
 
 
63 
 
60 
 
 
60 
 
 
60 
 
 
108 
 
202 
 
 
130 
 
91 
 
 
293 
 
333 
 
459 
 
 
215 
 
 
350 
 
 
 
Table 2.2: PCR programs used for the different genes 
 
Gene First denaturation 
(°C) 
 
Second 
denaturation (°C) 
Annealing 
(°C) 
Extension  
(°C) 
Final extension 
(°C) 
 
Cycles 
 
ADH2 exon 3 
 
ADH2 exon 9 
 
ADH3 exon 8 
 
ALDH2 exon 12 
 
Cyt 3A5*3 
 
SLUT 1A1 
 
GSTT1 
 
GSTM1 
 
 
95 
 
94 
 
95 
 
94 
 
94 
 
94 
 
94 
 
94 
 
95 
 
94 
 
95 
 
94 
 
94 
 
94 
 
94 
 
94 
 
55 
 
54 
 
53 
 
52 
 
55 
 
63 
 
60 
 
60 
 
72 
 
72 
 
72 
 
72 
 
72 
 
72 
 
72 
 
72 
 
 
72 
 
72 
 
72 
 
72 
 
72 
 
72 
 
72 
 
72 
 
 
35 
 
30 
 
35 
 
30 
 
30 
 
40 
 
35 
 
35 
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2.7.3. SNP genotyping by (RFLP) procedures: 
2.7.3. 1. RFLP analysis of ADH2 gene polymorphism in exon 3 using Mae III: 
ADH2 genotyping was done according to the method of Xu et al. [134]. 
Oligonucleotides PCR primers were used for ADH2 exon 3, F, 5’- 
AATCTTTTCTGAATCTGAACAG - 3’and R, 5’- GAAGGGGGGTCA CCAGGTTGC - 3’. 
PCR reactions were carried out on PCRexpress thermocycler using reagent kits from 
Promega. initial denaturation was performed at 95˚C for 2 minutes followed by 35 thermal 
cycles consisting of denaturation for 1min at 95˚C, annealing for 45 sec at 55˚C, extension 
for 45 sec at 72˚C and final extension for 5 min at 72˚C. After amplification, 15 µl of the 
PCR product was digested at 55˚ C for two hours with (0.5u) Mae III enzyme (Roche 
Diagnostic, Germany). Aliquots were electrophoresed on 3% agarose gels, a DNA size 
marker (M VIII) and an uncut fragment were run on every gel; bands were visualized with an 
ultraviolet translamunator. The mutant ADH2.2 allele contains a restriction site for Mae III, 
which is not present in the normal wild-type allele ADH2.1. The PCR amplified product is 95 
bp, the enzyme cut it into 60 bp and 35 bp fragments. 
3.7.3.2. RFLP analysis of ADH2 gene polymorphism in exon 9 using ALwN 1: 
ADH2 genotyping was done according to the method of Xu et al. [134]. PCR was 
done on PCRexpress thermocycler using reagent kits from Promega. Oligonucleotides 
primers for ADH2 exon9, F, 5’- TGGACTCTCACAACAAGCATGT-3’and R, 5’-
TTGATAACATCTCTGAAGAGCTGA- 3’ were used. Initial denaturation was performed at 
94˚C for 2 min followed by 30 thermal cycles consisting of denaturation for 30 sec at 94˚C, 
annealing for 30 sec at 54˚C, extension for 30 sec at 72˚C and final extension for 5 min at 
72˚C. After amplification, 15 µl of the PCR product was digested at 37˚ C for two hours with 
(2u) ALwN I enzyme (Biolabs, New England). Aliquots were electrophoresed on 2.5% 
agarose gels, a DNA size marker (M VIII) and an uncut fragment were run on every gel; 
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bands were visualized with an ultraviolet transluminator. The normal wild-type allele 
ADH2.1 contains a restriction site for ALwN I, which is not present in the mutant ADH2.3 
allele. The PCR amplified product is 202 bp. The wild-type allele is uncut and the mutant 
allele is cut by the enzyme into 132 bp and 70 bp fragments.  
 2.7.3.3. RFLP analysis of ADH3 gene polymorphism in exon 8 using SspI: 
ADH3 genotyping was done according to the method of Xu et al. [134]. 
Oligonucleotides PCR primers were used for ADH2 exon 8, F, 5’-
CTTTAAGAGTAAAGAATCTGTCC-3’ and R, 5’-ACCTCTTTCCAGAGCGAAGCAG- 
3’. PCR reactions were carried out on PCRexpress thermocycler using reagent kits from 
Promega. initial denaturation was performed at 95˚C for 2min followed by 35 thermal cycles 
consisting of denaturation for 1 min at 95˚C, annealing for 45 sec at 53˚C, extension for 45 
sec at 72˚C and final extension for 5 min at 72˚C. After amplification, 15 µl of the PCR 
product was digested at 37˚C overnight with (2u) SspI enzyme (Fermentas, Life science). 
Aliquots were electrophoresed on 2.5% agarose gels, a DNA size marker (M VIII) and an 
uncut fragment were run on every gel; bands were visualized with an ultraviolet 
transluminator. The normal ADH3.1 allele contains a restriction site for SspI, which is not 
present in the mutant ADH3.2 allele. The amplified product is 130 bp. The wild-type allele is 
cut by the enzyme into 67 bp and 63 bp fragments while the mutant allele is uncut.  
2.7.3.4. RFLP Analysis of ALDH2 gene polymorphism in exon12 using Mbo II:  
ALDH2 genotyping was done according to the method of Wu et al. [64]. PCR was 
done using the Primers for ALDH2 exon 12, F, 5’-CCACACTCACAGTTTTCTCTT-3’ and 
R, 5’-CCCTTTGGTGGCTAGAAGATG - 3, initial denaturation was performed at 94˚C for 
5min followed by 30 thermal cycles consisting of denaturation for 30 sec at 94˚C, annealing 
for 30 sec at 52˚C, extension for 30 sec at 72˚C and final extension for 7 min at 72˚C. 15 µl of 
the PCR product were digested with (2u) Mbo II at 37˚C overnight and then electrophoresed 
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on a 12% small polyacrylamide gel, stained for 10 min with (300 ml 1XTBE and 10 µl 
ethidium bromide), a DNA size marker (M VIII), a positive control and an uncut fragment 
were run on every gel; bands were viewed under ultraviolet transilluminator. Genotypes of 
ALDH2 exon12 were classified as follows: a normal homozygote, a heterozygote and a 
mutant homozygote. 
2.7.3.5. RFLP analysis of CYP 3A5 polymorphism in intron 3 using Ssp I:  
CYP 3A5*3 variant allele was investigated according to the method of Schaik et al 
[78]. PCR was done using PCRexpress thermocycler, reagent kits from Promega and primers 
for Cyt 3A5*3 F, 5’-CATCAGTTAGTAGACAGATGA-3’ and R, 5’-
GGTCCAAACAGGGAAGAAATA-3’ were used. Initial denaturation was performed at 
94˚C for 2 min followed by 30 thermal cycles consisting of denaturation for1min at 94˚C, 
annealing for 30 seconds at 55 ˚C, extension for 1 min at 72˚C and final extension for 7 min 
at 72˚C. The PCR products were digested with (3u) Ssp I enzyme (Fermentas, Life science) 
at 37˚C for two hours and subjected to electrophoresis on 3% agarose gels, bands were 
visualized with an ultraviolet translluminator. The amplified fragment is 293-bp, the normal 
wild-type allele has two cutting sites, the enzyme cut it into 148, 125, 20-bp fragments. The 
variant allele has only one cutting site which is different from that of the normal allele and 
the enzyme cut it into 168 and 125 bp fragments. The genotypes of CYP3A5 were classified 
as follows: a normal homozygote, a heterozygote and a mutant homozygote. 
2.7.3.6. RFLP analysis of SLUT 1A1 polymorphism in exon 7 using Hae II:  
SULT 1A1 alleles were investigated according to the method of Coughtrie et al. 
[114]. PCR was done using PCRexpress thermocycler, reagent kits from Promega and 
primers for SULT 1A1 Fwd 5’-GTTGCCTCTGCAGGGTCTGGAGAG-3’ and Rev 5’-
CCCAAACCCCCGTACTGGCCAGCACCC-3’ were used. Initial denaturation was 
performed at 94˚C for 2 min followed by 40 thermal cycles consisting of denaturation 
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for1min at 94˚C, annealing for 30 seconds at 63˚C, extension for 30 seconds at 72˚C and final 
extension for 5 min at 72˚C. The PCR products were digested with (3u) HaeI I enzyme 
(Promega) at 37˚C for six hours and subjected to electrophoresis on 3.5 % agarose gels, 
bands were visualized with an ultraviolet translluminator. The amplification product is 333-
bp fragment, the wild-type SULT1A1*1 allele has a cutting site for HaeII, the enzyme cut it 
into 168 and 165-bp fragments. The restriction site is not found in the variant SULT1A1*2 
allele. The genotypes of SULT 1A1 were classified as follows: a normal homozygote cut, a 
heterozygote and a mutant uncut. 
2.7.3.7. PCR-based analysis of GSTT1 and GSTM1genes (null- genotypes): 
GSTM1 and GST1 null- alleles were investigated according to the method of Arand et 
al [135]. Three sets of primers were used , primers to the region containing the deletion in the 
GSTM1 gene were used Fwd 5’-GAA CTC CCC TGA AAA GCT AAA GC-3’ and Rev 5’-
GTT GGG CTC AAA TAT ACG GTG G- then  primers to the region containing the deletion 
in the GSTT1 gene, Fwd 5’-TTC CTT ACT GGT CCT CAC ATC TC-3’ and Rev 5’-TCA 
CCG GAT CAT GGC CAG CA- 3’ which  corresponded to exon 5 and 6, and intron 5 [128],  
human albumin gene was co amplified as an internal control in all samples using the primers,  
Fwd 5’GCC CTC TGC TAA CAA GTC CTA-3’ and Rev 5’-GCC CTA AAA AGA AAA 
TCC CCA ATC- 3’. Initial denaturation was performed at 94˚C for 5 min followed by 35 
thermal cycles consisting of denaturation for 1 min at 94˚C, annealing for 1 min at 60˚C, 
extension for 1min at 72˚C and final extension for 5mins at 72˚C.  PCR products were 
electrophoresed on 2% agarose gels. A 459-bp fragment was amplified with the GSTT1 
primers and a 215-bp fragment was amplified with GSTM1 primers. The absence of the 
specific product of GSTM1 or GSTT1 in the presence of HAS gene product (350-bp) 
indicated the corresponding null genotype. Although this technique does not distingwish 
between homozygotes and heterozygotes of the positive genotypes, it identifies conclusively 
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the null-genotypes. 
2.7.4. Quality control: 
DNA extraction was done in different times. PCR amplification and genotyping of the 
different samples were conducted blindly.  A quality control sample as well as a blank control 
(without DNA template) was used on every PCR operation. A random selection of 10% of all 
the samples was repeated for genotyping and no discrepancies were discovered. Two 
independent readers interpreted the gel photographs. 
2.7.5. Theoretical considerations: 
There are two types of analysis that can be performed using data collected from a population 
of autosomal polymorphic markers. These are: 
I- Estimation of parameters summarizing the genetic variations within and between 
populations. 
II-  Analysis of genetic stratification and substructure within populations and population 
groupings. 
It is important to assess the importance of sample size and the number of genetic markers to 
be screened.  
2.7.6. Statistics and measures of genetic variations: 
There is a large body of theoretical work in the literature examining the question of sample 
size and the optimal number of loci required to derive meaningful estimates for most simple 
genetic parameters. The most commonly derived statistics from genotypic data are estimates 
of allele frequencies, heterozyosities and genetic distance. Estimates of locus heterozygosity 
and genetic distance between populations are calculated by considering data from a number 
of separate genetic markers. Their statistical accuracy is more heavily influenced by the 
number of loci than sample size. 
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 2.7.7. Statistical analysis: 
Data were checked and entered into the computer and they were analyzed using 
computer software SPSS for Windows (version 7.5). Parametric and nonparametric Parson’s 
Chi-square statistics was used to examine differences between patients and controls with 
regard to demographic variables and distribution of genotypes. Statistical differences were 
evaluated by using logistic regression analysis to compare genetic polymorphisms in ADH2, 
ADH3 and ALDH2, CYP3A5, GSTM1, GSTT1 and SULT1A1 between the cases and 
controls. A 5% level of significance was used in the analysis and the odds-ratio was estimated 
assuming 95% as the confidence interval (CI).  
 
 
Table 2.3: SNPs detected, location, restriction enzyme, amino acid change and effect on 
enzyme 
  
 
 
Allele 
 
Chrom. 
 
Nucleo 
 
A.A 
 
PCR/RFLP 
 
Enzyme activity 
Ref. No. 
 
ADH2*1  
ADH2*2  
 
ADH2*1  
ADH2*3  
 
ADH3*1 
 ADH3*2 
 
ALDH2*1  
ALDH2*2  
 
CYP3A5*1  
CYP3A5*3  
 
GSTM1  
GSTM1*0 
 
GSTT1  
GSTT1*0  
 
SULT 1A1*1  
SULT 1A1*2  
 
4q22 
,, 
 
4q22 
,, 
 
4q22 
,, 
 
12q24.2 
,, 
 
7q21 
,, 
 
1p13.3 
,, 
 
22q11.2 
,, 
 
 
exon3 G  
           A 
 
exon9 C  
           T 
 
exon8 A  
           G 
 
exon12 487G 
            487A 
 
6986A              
6986G 
 
presence 
deletion 
 
presence 
deletion 
 
exon7 638G 
          638A 
 
Arg47 
His 
 
Arg369 
Cys 
 
Arg271 
Gln 
 
Gln487 
 Lys 
 
- 
- 
 
- 
- 
 
- 
- 
 
Arg 
His 
 
Mae III - 
Mae III + 
 
AlwN I - 
AlwN I + 
 
Ssp I + 
Ssp I - 
 
Mbo II +2sites 
Mbo II +1site 
 
Ssp I +2sites 
Ssp I +1sites 
 
PCR positive 
PCR negative  
 
PCR positive 
PCR negative  
 
Hae II + 
Hae II - 
 
Normal 
Increased 
 
Normal 
Increased 
 
Increased 
Less activity 
 
Active 
Inactive 
 
Active 
Protein truncation 
 
Active 
No enzyme 
 
Active 
No enzyme 
 
Active 
Inactive 
 
 
[134,136] 
 
 
[134,136] 
 
 
[134] 
 
 
[63,64] 
 
 
[78] 
 
 
[135] 
 
 
[135] 
 
 
[114,137] 
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Results 
This is a case-control study comprising 134 patients with oesophageal cancer and 
healthy controls (n= 233 volunteers). Table 3.1 shows the demographic characteristics of the 
patients and controls. The mean age of the patients was 56.41 years and 47.87 years for the 
controls. The male/female ratio was 1.06:1. Most of the patients (68%) as well as the controls 
(61%) were of the Afro-Asiatic linguistic group (Figure 3.1). Both alcohol intake and 
smoking are significant risk factors for OC, (AOR= 3.3, P= 0.01) and (AOR= 2.23, P= 0.01) 
respectively. However, a considerable number of controls (32%) did not disclose whether 
they consume alcohol, neither did women confessed to be cigarette smokers. However, the 
overall frequencies of smokers and alcohol consumers were low in both patient and control 
groups. All tobacco smokers and alcohol consumers were males. Histological examination of 
the patient samples showed that 75% of OC was squamous cell carcinoma and 14% was 
Adenocarcinoma.  
 
Figure 3.1: The Different linguistic groups of the Study subjects 
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 45
Table 3.1: Demographic characteristics of the Sudanese oesophageal cancer patients and 
controls: 
    Cases                   Controls 
Characteristic   n (freq)       n (freq)            AOR (95% CI) p-value 
 
Age (years) 
 
<60     64 (48)              186 (80)  
>60    70(52)                47 (20) 
Total                                      134               233 
 
Sex 
 
Female             65 (49)               121(52)  
Male              69 (51)     112(48)                1.3(0.82-1.9) 0.28    
Total                                     134                233 
 
Linguistic group 
 
Afro-Asiatic                             91(68)                140(61)  
Nilo-Saharan                           33 (25)                 63(27)                    0.44(0.19-1.01) 0.052     
Niger-kordofanian                    8 (6)                   28(12)                    0.81(0.49-1.32) 0.4     
Unknown                                  2 (2)                     2(0)                      1.54(0.21-1.7) 11.1     
Total                                      134                 233 
 
Smoking 
 
No    102 (76)      141 (60)   
Yes      29 (22)        18 (8)              2.23(1.17-4.2) 0.01     
Unknown                                    3(2)                     74 (32)                  0.05(0.18-0.18) 0.00     
Total                                       134                    233 
 
Alcohol consumption 
   
No    113 (84)       152 (65)               1.00 
Yes      17 (13)          7 (3)               3.3(1.3-8.1) 0.01     
Unknown                                    4 (3)                 74(32)                    0.07 (0.03-0.2) 0.00     
Total                                       134                   233 
 
Histopathological types 
 
SCC                                         101(75) 
ADC                                          18(14) 
Others                                        15(11) 
Total                                        134                    
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3.1. SNP genotyping by PCR-RFLP procedures: 
The extracted DNA of the different samples was detected by electrophoresis on 2.0% 
agarose gel stained with ethidium bromide and visualized under UV light (Figure 3.2). Figure 
3.3 shows the analysis of the specificity of the PCR of the target fragment by electrophoresis 
on 2.0% agarose gel. Mutations in all genes used in this study were detected through 
polymerase chain reaction-restriction fragment length polymorphisms (PCR-RFLP) except 
for GSTM1 and GSTT1 null-genotypes. Figures 3.4 to 3.10 show RFLP of the different 
restriction digests.  
 
 
                                                   M     1      2      3      4     5 
 
 
Figure 3.2: Electrophoresis of the DNA on agars gel: M = SAmolecular weight marker 
(100bp, Roche), 1,2,3,4 and 5 = genomic DNA samples. Electrophoresis was carried out at 
145 volts for 5 min, (Detection by Ebor/UV illumination).  
 
                                               
 
                                                         1     2     3   B    M   
 
 
Figure 3.3: PCR Amplification of SULT1A1 gene in exon 7: M = molecular weight marker 
(50bp, Roche), B = blank (negative control), 1,2 and 3 = PCR products. Electrophoresis was 
done on 2.0% agarose gel, confirming the presence of amplifiable DNA in the samples. 
 
 
 
333bp 
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3.2. Allelic frequencies: 
Allele frequencies at each locus were determined for patients and controls using excel 
computer program. Eight loci were typed in 367 individual subjects, given a total of 2936 
individual genotypes, including the missing data. A wide range of analysis was performed 
using data from the eight SNP loci. The number of alleles detected at each locus was two 
alleles. A total of 32 allele frequencies were obtained (8 markers X 2 allele per locus X 2 
groups of subjects). 
3.2.1. Polymorphisms of Alcohol-Metabolizing enzymes: 
Table 3.2 shows the genotype distributions and allele frequencies of ADH2, ADH3 
and ALDH2 genes among the study subjects. The distribution of the wild-type, the 
heterozygous and the homozygous mutant genotypes of ADH2, ADH3 and ALDH2 were 
similar in patients and controls. There were no significant differences in the frequency 
distributions of the variant ADH2*2, ADH2*3, ADH3*2 and ALDH2*2 alleles between 
oesophageal cancer patients and healthy controls. The polymorphisms we studied featured 
genetically determined characteristics and should therefore remain unchanged with age, the 
age distribution would have no effect on the genotype frequency of subjects. Among the 
controls, the polymorphic alleles, ADH2*2, ADH2*3, ADH3*2 and ALDH2*2 occurred at 
frequencies 6%, 6%, 25% and 0% respectively. All genotype distributions of ADH and 
ALDH2 alleles fitted the Hardy-Weinberg equilibrium.  
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Table 3.2: Distribution of the ADH and ALDH2 genotypes and allele frequencies in the 
Sudanese subjects 
 
          Patients          Controls 
Genotype         n (freq)           n (freq)                 AOR (95% CI) p-value 
 
ADH2 
 
ADH2*1/*1        115(92)                 188 (89)           
ADH2*1/*2           8 (6)                     18 (9)                 0.73(0.31-1.7) 0.47     
ADH2*2/*2           2 (2)                       4 (2)                 0.82(0.15-4.5) 0.82  
 Total                                125                         210    
  
ADH2     
 
ADH2*1/*1        97(90)                  164 (90)           
ADH2*1/*3        10 (9)                     17 (9)               
ADH2*3/*3          1 (1)                       2 (1)   
Total                                108                         183       
 
ADH3 
 
ADH3*1/*1         67 (52)               118(54)           
ADH3*1/*2         55 (43)                 89(41)                1.09(0.69-1.7) 0.71         
ADH3*2/*2           6 (5)                   10(5)                  1.06(0.37-3.04) 0.91  
 Total                                128                         217        
 
ALDH2                                   
ALDH2*1/*1                   121(99)               213 (100)             
ALDH2*1/*2       1.0 (1)                 0.0 (0.0)                 0.73(0.31-1.7) 0.47                       
ALDH2*2/*2                    0.0 (0.0)              0.0 (0.0)                0.73(0.31-1.7) 0.47  
Total                                122                         213 
         
Allele frequencies 
 
ADH2*1                       95%                   94%   
ADH2*2   5%                     6% 
ADH2*1                       95%                   94%   
ADH2*3   6%                    6% 
ADH3*1                                74%                  75%    
ADH3*2             26%                  25% 
ALDH2*1             99.6%              100% 
ALDH2*2                              0.4%  0.0% 
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3.2.1. 1. ADH2 gene polymorphism 
Figures 3.4 and 3.5 show the RFLP patterns of the ADH2 gene. For the polymorphic 
locus in exon 3, the allele frequencies of the normal ADH2*1 and the mutant ADH2*2 
genotypes were similar in oesophageal cancer patients and controls (Table 3.2). 
Concerning the different linguistic groups (the Afro-Asiatic, Nilo-Saharans and the 
Niger-Kordofanians), they had nearly equal frequencies of the mutant ADH2*2 in both 
patients (25, 31, 25) and controls (28, 22, 19 respectively) shown in Table 3.3. 
   
                                     M      un     wt     wt    wt     wt     he    wt 
 
 
Figure 3.4: ADH2 RFLP using Mae III restriction enzyme: M = molecular weight 
marker (Marker VIII, Roche), un = uncut (108 bp), wt = wild type (95 bp), He = 
heterozygous. 
 
 
 
 
                                                M     1     2     3     4   un 
 
 
Figure 3.5:  ADH2 RFLP using AlwN I restriction enzyme: M = molecular weight 
marker (Marker VIII, Roche), un = uncut sample, 4 = heterozygous, 1,2,3 = mutant 
homozygous.  
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3.2.1. 2. ADH3 gene polymorphism 
Figure 3.6 shows the RFLP pattern of the ADH3 gene in exon 8. The frequencies of the 
highly active ADH3*1 and the low activity ADH3*2 allele were similar in oesophageal 
cancer patients and controls, Table 3.2. For the different linguistic groups, the Afro-
Asiatic, the Nilo-Saharans and the Niger-Kordofanians had nearly equal frequencies of 
the active ADH3*1 allele in patients (96, 95, 94) and in the control group (94, 91, 98 
respectively), Table 3.3.  
 
 
 
                                    M   wt   wt   he  he  wt    he  mt    wt  wt  wt   wt  wt  mt   
 
 
Figure 3.6: ADH3 RFLP using Ssp I restriction enzyme: M = molecular weight marker 
(Marker VIII, Roche), wt = wild type, he = mutant heterozygous, mt = mutant homozygous. 
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 3.2.1. 3. ALDH2 gene polymorphism 
Figure 3.7 shows a PAGE of ALDH2 gene (exon 12) digested with MboII, the use of 
PCR-RFLP method revealed that 0.4% of patients and none (0.0%) of the controls had the 
mutant ALDH2*2 allele (Table 3.2). In the patients the variant allele was found only in 
the Afro-Asiatic group. The homozygous ALDH2*2/*2 genotype was not observed in any 
of the subjects in this study. All of the different linguistic groups in both patients and 
controls had equal ALDH2 allele frequencies, presented in Table 3.3. 
 
                          
             
 
                                          M  un  1   2   3   4   5    6   7  8   he   
 
 
Figure 3.7: ALDH2 RFLP using Mbo II restriction enzyme:  M = molecular weight 
marker (Marker VIII, Roche), un = uncut sample (91 bp), 1-8 wild type (55, 26 and 10 bp), 
he, mutant heterozygous (65, 55, 26 bp). 
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Table 3.3:  Allele frequencies of the different genes among the study linguistic groups 
 
 
       Patients (freq)                                   Controls (freq) 
 
Allele                         AA         NS         NK                         AA          NS       NK 
         
ADH2*1                    75           69           75                          72           78          82                 
ADH2*2           25           31           25                          28           22          19 
     
ADH3*1           96           95           94                          94           91          98       
ADH3*2             4             5             6                            6             9            2   
                             
ALDH2*1                  99          100          100                       100          100        100  
ALDH2*2                  0.6          0.0           0.0                         0.0          0.0         0.0 
  
GSTM1*1                 43           52             67                        61           68           47 
GSTM1*0                 56           48             33                        38           32           54 
 
GSTT1*1                  19            14            17                         44           37          19 
GSTT1*0                  81            86            83                         56           63          81   
  
CYP3A5*1           30           48            71                         37           37           44 
CYP3A5*3                70           52             29                        63           63           56 
  
SULT1A1*1           82           84              71                        83           85         95   
SULT1A1*2              18           16              29                       19           14           5                   
 
 
AA = Afro-Asiatic  
NS = Nilo-Saharan                            
NK=Niger-Kordofanian   
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3.2.2. Polymorphisms of Xenobiotic-Metabolizing enzymes 
The allele frequencies and genotype distributions of CYP3A5, GSTM1 and GSTT1 among 
the study subjects are shown in (Table 3.4). Among the controls, the Hardy-Weinberg 
equilibrium rule was satisfied for both the CYP3A5 (P=0.073) and SULT1A1 genotypes 
(P=0.170).   
3.2.2. 1. CYP3A5 gene polymorphism 
Figure 3.8 shows the RFLP pattern of the different fragments of CYP3A5 gene. There were 
more homozygous CYP3A5*3/*3 carriers among patients compared to controls although this 
distribution was not statistically significant. There was no significant difference in the 
frequency distribution of the mutant CYP3A5*3 allele between oesophageal cancer patients 
(62%) and healthy controls (62%), Table 3.4. There were however differences in the 
distribution of the CYP3A5*3 allele in different linguistic groups, being highest among the 
Afro-Asiatics, followed by Nilo-Saharan and (52%) and the Niger-Kordofanian group had the 
lowest frequency in patients (29%). 
 
                                                            
                                                            M  1  2   3  4  5   6 
 
 
     Figure 3.8: CYP3A5 RFLP using Ssp I restriction enzyme: M = molecular weight 
marker, 2 = wild type (148, 125, 20 bp), 1,5 = heterozygous,  3,4,6 =  mutant (168, 125 
bp). 
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3.2.2. 2. GSTM1 and GSTT1- null genotypes 
Figure 3.9 shows the PCR-based electrophoresis of GSTM1 and GSTT1 on 2.5% 
agarose gel. The frequencies of GSTM1 and GSTT1-null genotypes were higher in 
oesophageal cancer patients (53% & 82%) than in the control group (39 & 61% 
respectively) shown in Table 3.4. For the GSTM1 null odds ratio (OR) was 1.8, P= 0.02 
and for the GSTT1 null OR was 2.96, P= 0.00.   
The frequencies of GSTM1 and GSTT1-null genotypes were higher in oesophageal 
cancer patients (53% and 82%, respectively) compared to the control group (39% and 
61%, respectively). Both the homozygous GSTM1 and GSTT1 genotypes were associated 
with increased risk of oesophageal cancer (OR 1.8 and OR 2.9, respectively) (Table I). 
Among the oesophageal cancer patients, the Afro-Asiatic and the Nilo-Saharan groups 
had the highest frequencies of the homozygous GSTM1*0 genotype (56% and 48%, 
respectively), whereas, the frequency was very low among the Niger-Kordofanians 
(33%). For the GSTT1*0 allele, the Afro-Asiatic and the Nilo-Saharans had the highest 
frequencies among patients (81% and 86%, respectively) compared to the controls (56% 
and 63%, respectively). There was no significant difference (83% and 81%) in their 
frequencies among patients and controls in the Niger-Kordofanian group.   
                                                      M     1     2    3      B    4    5        
 
 
Figure 3.9: Agarose gel electrophorestic results of the PCR products of GSTM1 and 
GSTT1 and the internal control: M = molecular weight marker (Marker VIII, Roche), B = 
blank (negative control); 1 = positive for     both GSTM1 (215bp) and GSTT1 (459bp), 2 = 
negative for GSTM1 and positive for GSTT1, 3 = positive for GSTM1 and negative for 
GSTT1, 4,5 = negative for both GSTM1 and GSTT1 but positive for the internal control 
(350bp). 
459bp 
350bp 
215bp 
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Table 3.4: Distribution of the CYP3A5, GSTM1 and GSTT1 genotypes and allele 
frequencies in the Sudanese subjects 
 
               Cases          Controls 
Characteristic             n (freq)          n (freq)           AOR (95% CI) p-value 
 
 
CYP3A5 genotype 
 
CYP3A5*1/*1                         25 (23)          37 (18)                            
CYP3A5*1/*3                         31 (29)          81 (40)            0.57 (0.29-1.1) 0.09                        
CYP3A5*3/*3                         52 (48)          87 (42)            0.88 (0.47-1.6) 0.7     
Total              108          205 
 
CYP3A5 Allele frequencies 
 
CYP3A5*1                          81 (38) 155 (38) 1.00  
CYP3A5*3                        135 (62)            255 (62) 0.98 (0.70-1.39) 0.940 
Total               216             410 
  
GSTM1 genotype  
 
GSTM1*1                               53 (47)          124 (61)                                                          
GSTM1*0                60 (53)            79 (39)             1.8 (1.11-2.83) 0.02                                               
Total             113           203 
 
GSTT1 genotype  
 
GSTT1*1                                20 (18)             79 (40)                                                            
GSTT1*0                93 (82)           124 (61)          2.96 (1.7-5.2) 0.001   
Total             113            203                                                        
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The frequency of GSTM1*0 allele among the different linguistic group of OC patients 
41%
35%
24%
Afro-Asiatic
Nilo-Saharan
Kango-Kordofanian
 
Figure 3.10: The frequency of GSTM1*0 among the different linguistic groups of OC 
patients  
 
 
The frequency of GSTT1*0 allele among the different linguistic groups of OC 
patients
32%
35%
33%
Afro-Asiatic
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Kango-Kordofanian
 
Figure 3.11: The frequency of GSTT1*0 among the different linguistic groups of OC 
patients 
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3.2.2. 3. SULT1A1 gene polymorphism 
Figure 3.4 shows the RFLP pattern of the SULT1A1 gene. The allele frequencies and 
genotype distributions of SULT1A1 among the study subjects are shown in (Table 3.5). 
The common SULT1A1*1 allele and the minor SULT1A1*2 allele occurred at an equal 
frequencies in patients (82% and 18%) and in control subjects (85% and 15%). The 
genotype distributions of SULT1A1 were found to be SULT1A1*1/*1 (66%), 
SULT1A1*1/*2 (32%) and SULT1A1*2/*2  (2%) in patients compared with respective 
SULT1A1*1/*1 (70%), SULT1A1*1/*2  (29%) and SULT1A1*2/*2  (1%) in control 
subjects. All of the different linguistic groups in both patients and controls have equal 
SULT1A1 allele frequencies, presented in Table 3.3. However, the Niger-Kordofanian 
group had slightly higher frequency of the mutant SULT1A1*2 among patients (29%) 
compared to controls (5%).  
 
 
 
 
 
                                               M  mt  he  he he he      he mt  he  he he wt he 
 
Figure 3.12: SULT 1A1 RFLP using Hae II restriction enzyme: Lane M =   molecular 
weight marker; wt = wild type homozygous, mt = mutant homozygous, he = heterozygous. 
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 Table 3.5: SULT1A1 genotype prevalence and allele frequencies in the Sudanese subjects 
 
 
    Cases            Controls  
Characteristic   n (freq) n (freq) AOR (95% CI) p-value 
 
 
SULT1A1 genotype  
 
SULT1A1*1/*1            74 (66)          137 (70)                                
SULT1A1*1/*2            36 (32)            56 (29)            1.2 (0.72-1.97) 0.5     
SULT1A1*2/*2               2 (2)                1 (1)              3.7 (0.33-41.5) 0.3 
Total             112           194 
 
Allele frequencies 
 
SULT1A1*1                        184 (82) 320 (85) 1.00 
SULT1A1*2                            40 (18)            68 (15) 0.97 (0.75-1.29) 0.918 
Total              224  388  
 
 
 
 
 
Table 3.6: Results of quality control sample (2B) genotyping 
 
 
    Gene                  Exon                                 Allele 
 
 
   
 
 
ADH2                                                    3                                          1*1 
 
ADH2                                                    9                                          2*2 
 
ADH3                                                    8                                          1*1 
 
ALDH2                                                12                                          1*1 
 
CYP3A5*3                                        intron 3                                    1*3 
 
SULT1A1                                             7                                           1*2 
 
GSTM1                                                  -                                             +   
GSTT1                                                   -                                             + 
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DISCUSSION 
 Within Sudan oesophageal cancer is more prevalent in the North than in the South [138], and 
is strongly associated with the habit of placing tobacco under the tongue and alcohol 
consumption [139]. This is a case-control study comprising 134 patients with oesophageal 
cancer and 233 healthy controls and is the first study in Sudan to investigate the correlation 
between polymorphisms of carcinogens-metabolizing enzymes and risk of oesophageal 
cancer. Most of the patients were the linguistic group of Afro-Asciatic origin similar to the 
controls. Although the study is hospital based there is limited role for selection bias because 
almost all suspected OC cases were referred only to the participating hospitals, therefore only 
few cases were missed. However, only those patients being able to travel to Khartoum were 
included in this study. Concerning their residence 76% of our patients are rural residents 
where life style patterns are relatively simple because of limited food choices. The low 
socioeconomic status and the poor nutrition of our patients may play role in the causation of 
OC in Sudan.  In this study patients and controls were similar with respect to female and male 
ratio (51% male in patients and 48% in controls). However, the age was not matched as there 
was a significant difference between the mean age of patients (56 years) compared with the 
controls (48 years) and this indicated that our patients are older than the controls. The study 
showed that the disease is equally prevalent in females and males and this is almost similar 
with the reported ratio by RICK (1:1.3) male/female. The observation of equal risks among 
males and females in our study is supported by the reported oesophageal cancer in Sudan 
having a relative female preponderance [138]. These Sudanese results differ from what is 
reported in the rest of the world being 4:1 male preponderance [14]. The risk of OC for the 
indigenous South African was higher affecting males three times more than females. Those 
differences could be due to different gene-environment interactions. The indigenous South 
African males are at higher risk of oesophageal cancer due to lifestyle exposures [15,140]. 
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However, the aetiology that makes Sudanese females to be at higher risk is not known. There 
is therefore a need for more epidemiological studies investigating the other exposures that 
may be operating in increasing susceptibility to oesophageal cancer in the Sudanese 
environment. In this study the frequencies of smokers and alcohol consumers were low in 
both patients and controls and for cultural reasons, all tobacco smokers and alcohol 
consumers were males. With respect to histology most of the histological types of cases were 
squamous cell carcinoma (75%) as well as adenocarcinoma (14 %).  
There are many risk factors for the development of OC with each factor varying between 
different geographical areas. Alcohol drinking is a major risk factor for oesophageal cancer 
and its impact may be modulated by levels of ADH and ALDH2 enzymes. Alcohol is 
principally metabolized to acetaldehyde which is eventually converted to acetate through the 
actions of enzymes belonging to the alcohol dehydrogenase (ADH) and aldehyde 
dehydrogenase (ALDH2) families. Acetaldehyde is a confirmed carcinogen thus its 
accumulation because of variability in the expression of ADH and ALDH2 enzymes due to 
genetic polymorphisms, could lead to increased susceptibility to oesophageal cancer. While a 
lot of studies have investigated the effects of polymorphisms in these genes, very little is 
known about their role in oesophageal cancer susceptibility among especially indigenous 
Africans. In this study, the contribution of this polymorphism to oesophageal cancer risk has 
been investigated in Sudanese OC patients and unrelated healthy controls using polymerase 
chain reaction/restriction fragment length polymorphism analysis (PCR/RFLP). We found 
that the frequency of the variant ADH2*2 allele among patients and controls (5% and 6%, 
respectively) are higher than those reported among Caucasians and Xhosa speaking South 
Africans (Dandara et al., personal communication) but much less than the reported among 
Asians (up to 55%)  [141]. ADH2*2 which is associated with up to 100 times more activity 
compared to the normal ADH2*1, can result in the fast accumulation of acetaldehyde. 
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However acetaldehyde produces unpleasant effects resulting in carriers of such genotype 
avoiding alcohol consumption. In this study the ADH2*2 allele was not associated with 
increased risk of oesophageal cancer and this could have been due to carriers of this allele not 
tolerating alcohol. The study also showed that the frequencies of the variant ALDH2*2 allele 
in oesophageal cancer patients and controls (0.4% and 0%) were comparable with the 
reported value for the African [66]. The homozygous ALDH2*2/*2 genotype was not 
observed in any of the subjects in this study. Our results showed no significant differences in 
the frequency distribution of ADH2*2, ADH2*3, ADH3*2 and ALDH2*2 alleles between 
oesophageal cancer patients and healthy controls. Among the controls, the polymorphic 
alleles in the alcohol metabolizing genes, ADH2*2, ADH2*3, ADH3*2 and ALDH2*2 
occurred at frequencies 6%, 6%, 25% and 0% respectively. This study has shown for the first 
time the distribution of ADH2, ADH3 and ALDH2 genotypes in the Sudanese population. 
More studies are needed that would investigate polymorphisms in the genes that encode for 
enzymes metabolizing constituents of tobacco smoke since the use of tobacco is becoming 
much more common among Sudanese subjects. The fact that these results did not show an 
association between oesophageal cancer and the polymorphisms in genes controlling alcohol 
metabolism can be ascribed to the fact that patients and controls were from the whole 
Sudanese population without targeting specific ethnic backgrounds, however there were not 
enough numbers to stratify these into different ethnic groups and hence this lack of 
concordance. Another factor which must be considered is that alcohol consumption in a 
mostly Muslim community is a social stigma and therefore easily denied making the number 
of unknowns significantly high. This is true also for smoking among women which is 
culturally un-welcomed. 
Xenobiotic-metabolizing enzymes are expressed in most extra-hepatic tissues including the 
human gastrointestinal tract where they provide in situ protection from toxic or carcinogenic 
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components.Most carcinogens that humans are exposed to through diet, drugs and lifestyles 
such as smoking, are metabolically oxidized by a group of enzymes classified as phase I 
enzymes and include cytochrome P450s (CYPs). The resultant products of metabolism are 
reactive and readily react or bind to cell macromolecules including DNA and proteins 
forming adducts. Sometimes this interaction is a recipe for cancer initiation.  However, the 
human body has another group of enzymes that is responsible for the removal of the reactive 
intermediates generated from phase I metabolism and is referred to as phase II. Phase II 
enzymes accomplish their role by conjugating the reactive intermediates thereby facilitating 
their removal from the body through mostly the mercapturic acid pathway. The phase II 
group of enzymes includes such families of enzymes as glutathione S-transferases (GSTs), N-
acetyltrasferases (NATs) and sulphotransferases (SULTs) [71]. Differences in 
biotransformation activities may provide protection from certain xenobiotic or increase 
toxicity of others and the imbalance between phase I and phase II enzymes may contribute to 
the development of cancer. Individual susceptibility to oesophageal cancer may be partly due 
to genetic differences in genes controlling the metabolic balance between the activation (by 
CYPs) and detoxification (by GSTs or SULTs) of pro-carcinogens in the environment. In this 
study we investigated a potential correlation between gene polymorphisms in phase I 
(CYP3A5) and phase II (GSTM1, GSTT1 and SULT1A1), alone or in combination and the 
risk of oesophageal cancer using PCR-based RFLP analysis. The study is the first among the 
Sudanese and will help compare with what is reported in other populations. In contrast to the 
findings of Dandara et al. (2006), we did not find any significant association between genetic 
polymorphism in CYP3A5 gene with oesophageal cancer. There are possible reasons for our 
observation, the first being that possibly, due to different environmental exposures, different 
genetic variants are important in different geographical settings. It could be possible that 
while South Africans could be exposed to carcinogens that are substrates of CYP3A5, the 
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Sudanese population might exposed to other carcinogens which do not need this gene for 
detoxification. After all, it is the gene-environment interaction which is important. The 
second reason for our results could be due to the extreme racial mixing of the Sudanese 
people, it is possible that different variants may be genetically linked with different 
mutations. Therefore, care must be taken when analyzing data from a population composed 
of subjects from different ethnic groups.  
The lack of an effective detoxification system might be a risk factor for oesophageal cancer. 
Indeed, the GST family catalyzes reactive carcinogenic intermediates that are produced 
through the metabolism of environmental toxins by CYP450s. GSTM1 and GSTT1 are 
polymorphic and are commonly absent in human populations. This study showed that the 
polymorphisms in GSTM1 and GSTT1 were associated with increased risk for oesophageal 
cancer further pointing to a possible role of these genes in the detoxification of intermediates 
of phase I metabolism. There is a significant association between patients and control groups 
for GSTM1-null allele (p= 0.02 and OR=1.8) and for GSTT1-null allele (p= 0.00 and 
OR=2.9). Interestingly the frequency of the GSTM1-null genotype in our control group 
(38.9%) is exactly similar to what was reported previously in west (38%) and central (39%) 
Sudanese populations, by Tiemersma et al [142]. This may confirm that our control 
population correctly reflects the Sudanese population. However, the frequency of the GSTT1-
null genotype in our controls (61%) was found to be different from that reported in western 
(38.2%) and central (37.5%) Sudanese populations. Individuals with the null genotypes for 
both M1 and T1 (48%) are at a significant higher risk for developing oesophageal cancer than 
those with both genes present (12%). Our results are in agreement with a study done by 
Nimura et al [143] that showed an association between GSTM1 null genotype and 
oesophageal cancer. The influence of this polymorphism was already determined in other 
cancers such as oral, gastric and lung cancers [144,145,146], which will lead to the 
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hypothesis that a GSTM1 or GSTT1 deletion contributes to the genesis of oesophageal 
cancer.   
SULT1A1 is an important enzyme in phase II reaction of xenobiotic-metabolism. The 
frequency of the SULT1A1 gene showed a wide variation among different ethnic groups. 
Little is known of the role of SULT1A1 polymorphism in disease susceptibility and a few 
case-control studies have been published with regard to the association between the 
SULT1A1 polymorphism and risk of certain cancers. Our data showed no significant 
difference in SULT1A1 allele distribution between cases and controls, the common 
SULT1A1*1, Arg213 allele and the minor SULT1A1*2, His213 allele occurred at equal 
frequencies in patients (82.1% and 17.9%) and in control subjects (85.1% and 14.9% 
respectively). The frequency of the wild-type SULT1A1*1 allele was higher in Asiatic 
(Chinese and Japanese) than Caucasians (German, American, British) and African (Nigerian) 
populations [110]. Previous study in an African population (Nigerians) done by Coughtrie et 
al [114], showed that the frequency of SULT1A1*1 allele was 73% and that of SULT1A1*2 
allele was 26.9%. Our findings revealed no associations between the SULT1A1 G638A gene 
polymorphism and oesophageal cancer risk.  Other results showed strong association between 
SULT1A1 (G638A) genotype and the risk of oesophageal cancer risk in a Chinese population 
reported by Wu et al [147]. We also observed that there is no significant link between the 
SULT1A1 genotype (Arg213His) and age, these results are different from that reported by 
Coughtrie et al [114] who demonstrated a statistically significant increase in the 
SULT1A1*Arg213 allele compared to SULT1A1*His213 with increasing age. Our study did 
not find any evidence for interaction of SULT1A1 with smoking. SULT1A1 is involved in 
the activation of some carcinogens and the inactivation (detoxification) of others, this dual 
role of the enzyme indicates the complexity of the issue. In future epidemiological studies it 
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is important to study the function of SULT1A1 in more detail taking into account the 
corresponding environmental exposure.  
This study did not find a statistically significant correlation between CYP3A5*3, GSTM1 & 
GSTT1-null genotypes and age.  The age of onset of oesophageal cancer was similar for 
patients with any genotype. Concerning ethnicity, we also did not find a statistically 
significant difference between the groups. It is possible that other factors such as exposure to 
certain carcinogens or life style may influence this result. Environmental variables such as 
dietary habits and air pollutants are very difficult factors to analyze.  
It was really difficult to classify the subjects into the three different groups. Also, it was not 
possible in our case to study only a particular group due to the small sample. Possible effects 
of the CYP3A5 and SULT1A1 variants could be masked by variation of distribution of the 
variants in the different linguistic groups. The incidence of oesophageal cancer is still very 
low in Sudan as a whole compared to other nations. However, there is a clear tendency that 
people from North-eastern Sudan (mostly Bija ethnic group) showing high prevalence of 
oesophageal cancer specially among females and factors pertaining to this must be sought in 
future studies. 
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CONCLUSIONS 
- Oesophageal cancer is a health problem in part of the Sudan. 
- Our results strongly indicated that RFLP genotyping is simple to perform and provides 
results within 24 hours, the method requires a small blood samples and it can be used as a 
sensitive and specific genotyping method for carcinogen-metabolizing genes, it may be a 
useful tool in future characterization of interindividual differences in those genes. 
- There were no significant difference in the frequency distribution of ADH2*2, ADH2*3 
ADH3*2, and ALDH2*2 alleles between oesophageal cancer cases and controls.  
-  This study showed that the CYP3A5 and SULT1A1 (G638A) single nucleotide 
polymorphism is not genetic susceptibility biomarkers for the development of oesophageal 
cancer in Sudanese however; it has demonstrated an association between the GSTM1 and 
GSTT1-null genotypes and oesophageal cancer risk. Due to the importance of the GST 
enzymes in defense against potential environmental carcinogens, additional studies should 
be undertaken to fully determine its contribution to oesophageal cancer. Analysis of a larger 
number of individuals is necessary to further confirm these findings which may provide a 
useful public health approach for early detection and prevention of oesophageal cancer.   
- This is the first analysis involving polymorphism of carcinogen-metabolizing enzymes and 
oesophageal cancer risk among Sudanese and it has shown for the first time the distribution 
of ADH2, ADH3, ALDH2, CYP3A5, and SULT1A1 genotypes in the Sudanese 
population. 
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RECOMMENDATIONS 
 
In the future it will be interesting to: 
- Establish current rates of oesophageal cancer in high risk areas north-eastern Sudan.  
- Analyze several genes (candidate genes) in the susceptible population and to correlate 
genetic analysis with well defined epidemiological studies. 
- Investigate polymorphisms in the genes that encode for enzymes that metabolize 
constituents of tobacco smoke since the use of tobacco is much more common among 
Sudanese subjects. 
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APPENDIX I 
1. Equipments: 
- Autoclave, Bench centrifuge, Microcentrifuge, Microwave oven, pH meter, Raks, glass 
plates, - Micropipettes (P10, 20, 50, 100, 1000µl), Steril DNase free pipette tips, Laboratory 
parafilm, Vortex mixer, Water baths with shaker (37 ºC & 50 ºC) and Weighing balance 
used in this research are general laboratory equipments at the Departments of Biochemistry 
Faculty of Medicine in University of Khartoum and University of Cape Town. 
- Large vertical polyacrylamide electrophoresis tank 
- Low voltage electrophoresis power supply (500V, Pharmacia Fine Chemical, Sweden) 
- Orbital Shaker 
- PCR thermocycler (a programmable PCR-express, UK) and (GeneAmp PCR system, 
Applied Biosystem USA) 
- Small horizontal Gel electrophoresis Apparatus (Life Technologies, USA) 
- UV. Spectrophotometer (Beckman epectrophotometer, USA), 
- UV transluminator and gel documentation system (Uvidec Icd and Uvtec BTS.20M, 
White Head Scientific, made in EEC) 
 
2. Chemicals: 
Acrylamide, Agarose, Ammonium acetate, Ammonium persulfate, Bisacrylamide, 
Boric acid (orthoboric acid), Bromophenol blue, Chloroform, Distlled water, EDTA, Ethanol 
(70% & 100%), Ethidum bromide, Guanidine HCl, HCl, Isoamyl alcohol, KH2PO4, MgCl2,  
NaCl, Na2HPO4, Nalaurylsarcosinate, Sucrose, TEMED, Tris, Triton 100X, Phenol, SDS 
sodium dodasile sulphate, Xylene cyanol. 
 
 
 85
3. Reagents: 
- DNA isolation kit (FlexGene Kit, Qiagen-Hiilden Germany and NucleosSpin Blood 
QuickPure Kit, Machere-Nagel, Duren, Germany). 
- Proteinase K (Cat. No.  3940.01-6,  Amersham-Pharmacia Biotech. USA). 
- Ribonuclease A (Cat. No. 7019uZ, USB Corporation 2002, USA). 
- 100 bp DNA ladder (Cat. No. G2101, Promega Product Information, Promega,  )  
- DNA Molecular Weight Marker VIII (0.019-1011Kbp) (Cat. No. 1336045, Roche 
Dignostic GmbH, Roche Applied Science, Germany). 
- Gotaq polymerase (5u/µl, Promega/MADISON WI, Promega USA). 
- ALwN 1 Restriction Enzyme (Cat. No. R0514L, Biolabs, New England, USA) 
- Hae II Restriction Enzyme (Cat. No. R6661, Promega Corporation, USA) 
- Mae III Restriction Enzyme (Cat. No. 10822248001, Roche Applied Science, Germany) 
- Ssp I Restriction Enzyme (Cat. No. ER0771, Fermentas Life Sciences, UK) 
4. Solutions and buffers: 
Parazer’s rapid DNA extraction method: 
- Cell lysis buffer (pH 8.0): 
      109.5g Sucrose 
      5 ml 1M stock MgCl2 
      10 ml 1M stock Tris (pH 7.6) made up to 850 ml with water           
      10 ml Triton X100 
                    (Made up to 1 liter with water and stored at room temperature) 
- Wash buffer (pH 8.0): 
0.58g NaCl 
3.72g EDTA 
              (Made up to 1 liter with water and stored at room temperature) 
- Sarkosyl solution (20% Na laurylsarcosinate, Sigma L5125) 
20g in 100 ml water (frozen in aliquots)  
- Ammonium acetate solution (7.5 M) 
57.8 g in 100 ml water (Kept in the freezer) 
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- Proteinase K (10 mg/ml)  
- Guanidine HCl (6.0M) (Kept in the fridge) 
57.3g in 100 ml water 
- TE buffer (Tris HCL 10 mM, EDTA 1 mM at pH 8.0) 
1 ml (1M) Tris 
1 ml 100 mM EDTA (0.1M) 
             (Made up to 100 ml solution) 
- Ethanol (absolute) 
Salting out method:  
- PBS (1 mM KH2P04, 154mM NaCl, 5.6 mM Na2HP04; pH7.4)- 1 liter:  
-     KH2P04                                  0.136 g 
             NaCl                             9.0 g 
             Na2HP04                            0.795 g 
-   Sucrose Triton X-lysing Buffer 
          1 M Tris-Hcl, pH8    10 ml 
          1 M MgCl2     5 ml 
          Triton X-100     10 ml 
Made up to 1 liter with distilled water, Autoclaved and kept at 4 degrees 
109.5 g sucrose (D (+) saccharose) was added just before use (i.e. 11 g/100mL). The solution 
can not be stored with sucrose 
-  T20E5, pH8 
                   20 mM Tris-HCl 
                   5 mM EDTA 
- Proteinase K (stock of 10 mg/mL) 
-  Saturated NaCl 
  100 mL of sterile water was taken and 40g NaCl was added to it slowly until absolutely 
saturated.  It was agitated before use and NaCl was let to precipitate out. 
 
DNA extraction from tissue: 
Oesophageal biopsy or resection specimens were used for genomic DNA extraction.  
- Digestion buffer:                        100 ml 
100 mM NaCl                             2 ml 
10 mM Tris.Cl (pH 8)                 1 ml 
25 mM EDTA (pH 8)                  5 ml 
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0.5% SDS (Sodium dodasile sulphate) 
- Phenol/chloroform/isoamyl alcohol 
- PBS 
- Ammonium acetate (7.5M) 
- Ethanol (100% and 70%) 
- TE buffer (pH 8.0) 
- DNase-free RNase (1µg/ml) 
- Proteinase K (0.1 mg/ml) 
 
Electrophoresis of the extracted DNA in agarose gel: 
- 10X TBE (pH8.3) 
108g Tris 
55g boric acid (orthoboric acid) 
9.3g Na2 EDTA.2H2O 
The above reagents are mixed and made up to 1litre solution with distilled water. 
- DNA loading buffer 
2.5 mg bromophenol blue (2.5%) 
2.5 mg xylene cyanol (2.5%) 
0.4g sucrose (40%) 
The above reagents are mixed and made up to 1ml solution with distilled water. 
 
ALDH2 RFLP genotyping:  
- For 30 ml 12% Polyacrylamide gel: 
- 9 ml of 40% 19:1 acrylamide:bisacrylamide 
- 1q13.33 ml of 10XTBE 
- water up to 30 ml 
- 300 µl APS (10%) 
-  30 µl TEMED 
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APPENDIX II 
 
Questionnaires 
A questionnaire for oesophageal cancer patients 
-Health Center:…………………………………………………………..………….……..…… 
-Date of interview:…………....……..Interviewer…………………………..………..…..……. 
-Serial No:………………………………………………………………………….……..…… 
- Name:……………………………………………….………….……………...……….…..… 
-Age (Date of birth):……………………..……Place of birth………….…………….…..…… 
- Sex:…………….……...Male………….……..……...Female…..…………………..…..…… 
-Tribe:…………………………………………………….…………………...…………….… 
- Residence for the last 10 years:……………………………………………………………… 
- Do you know what Oesophageal Cancer is? Yes…………………………..No…..…...…..…  
- Has any one in your family had (OC)? Yes…………….No….……. If yes who…….……… 
- Do you have any other cancer in the family? Yes………………………..No……….…....…. 
- What type of cancer…………………………………………………….………..……....…… 
- Stable Food:             - Wheat …….….…      - Sorghum …….….……     - Maize …..…..….. 
- Smoking:……………………………………………………………………………………… 
- Alcohol intake:…………………………………………….…………………….….………... 
-Tumor Site:……………………………………………….……………………….…………... 
Remarks………………………………………….……………….………….………….………
……………………………………………….………………………………….…….…...……
……………………………….…………………………………………………….……………
………………………………………………………………………………………………..… 
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Interview schedule for controls 
 
 
- Date of interview:……………………………..…Interviewer:…………………………..…. 
 
- I.D. No…………………………………………………………..…………………………… 
 
- Age:……………………………………………………...….…………..…………………… 
 
- Sex:………………………………………………………………......………………………. 
 
- Do you know what oesophageal cancer is?………………………………….………………. 
 
- Has any one in your family had oesophageal cancer?……………………………….…….… 
 
- Do you have any cancer in the family?……………………………………….………...….… 
 
- What type?…………………………………………………………..…………….….……… 
 
- What is your tribe?……………………………………………………….…………………… 
 
- What language do you speak most at home?……………………………………....………… 
 
- Where were you born?  Urban…………..……….……Rural……………………..…………. 
 
- Where do you normally live & how long you lived there?…………………………………… 
……………………………………………………………………………………………..……
…………………………………………………………………………………..……………… 
- What is your stable food?………………………………………………....…………………. 
 
- Where do you normally cook food?     Inside…………………….Outside…………………. 
 
- What type of fuel do you mostly use in your home for cooking?…………………………… 
 
  and for the last 20 years?…………………………………………………………………….. 
 
- In any of the houses you lived in, did the smoke make your eyes water……………………. 
 
- Have you ever smoked cigarettes regularly? Now……...…in the past…….…. Never…….. 
 
- Have you ever drunken alcohol? Now…………..In the past……………..Never…………... 
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Abstract:  
There are many risk factors associated with the development of oesophageal cancer and 
including tobacco smoking and alcohol consumption. The genes that encode enzymes 
involved in alcohol metabolism, alcohol dehydrogenases (ADH) and aldehyde 
dehydrogenases (ALDH2) are polymorphic. In some populations, the high-activity isoforms 
of ADH (ADH2*2 and ADH3*1) and the low-activity form of ALDH2 (ALDH2*2) have been 
shown to be associated with alcohol-related carcinogenesis. In this study, the contribution of 
this polymorphism to oesophageal cancer risk has been investigated in 134 Sudanese patients 
with oesophageal cancer and 233 unrelated healthy controls using polymerase chain 
reaction/restriction fragment length polymorphism analysis (PCR/RFLP). There were no 
significant differences in the frequency distribution of ADH2*2, ADH2*3, ADH3*2 and 
ALDH2*2 alleles between oesophageal cancer patients and healthy controls. The 
homozygous ALDH2*2/*2 genotype was not observed in any of the subjects in this study. 
Among the controls, the polymorphic alleles in the alcohol metabolizing genes, ADH2*2, 
ADH2*3, ADH3*2 and ALDH2*2 occurred at frequencies of 6%, 6%, 25% and 0%.   
Keywords: Oesophageal cancer, alcohol dehydrogenase, aldehyde dehydrogenase, genetic 
polymorphism 
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1. Introduction 
Globally the incidence of oesophageal cancer varies significantly by geographic regions, race 
and gender. As a group, Chinese are particularly susceptible to oesophageal cancer, with half 
of all (oesophageal cancer) in the world occurring amongst the Chinese [1]. The disease is 
relatively rare among Caucasians and it occurs more frequently among men than women 
(men are affected four times more frequently than women). The disease usually affects those 
over middle age [2]. 
High incidence areas in Africa include several East African countries (South Africa, 
Mozambique, Zimbabwe, Tanzania, Kenya and Uganda). In those countries there are a 
number of high incidence foci: the Transkei in South Africa, amongst the Kukuyu near Lake 
Victoria in Kenya, amongst the Usukuma in Tanzania and amongst the Ngomi in the east of 
Zambia and Zimbabwe [3]. In Sudan, data on cases of oesophageal cancer seen in Radiation 
and Isotopes Center in Khartoum (RICK 2001-2005) revealed that there is a clear increase of 
the disease in the north eastern part of the country and that oesophageal cancer is the ninth 
most common cancer. The incidence of the disease is about 6% of the total cancers with 
nearly 200 people diagnosed each year. Contrary to reports among other populations such as 
South Africans [4] and Chinese, where the disease is more prevalent among males, in Sudan, 
females are equally affected as males. 
 In this study the role of polymorphisms in the genes coding for alcohol metabolizing 
enzymes were investigated since alcohol has been shown in many studies to be one of the 
major risk factors for oesophageal cancer.  
There are two groups of enzymes principally involved in the metabolism of alcohol, alcohol 
dehydrogenase (ADH) which catalyses the conversion of ethanol to acetaldehyde and 
aldehyde dehydrognase (ALDH2) which further metabolizes the acetaldehyde to acetate [5]. 
Humans have at least six loci encoding ADH (ADH1-6) and these genes are found on the 
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same chromosomal region 4q22. The gene products occur either as homo- or heterodimers 
forms [6]. Polymorphism occurs at two of these loci (ADH2 and ADH3) [5]. The highly 
active ADH2*2 allele which results from the substitution of arginine at amino acid position 
47 by histidine has been reported at frequencies of more than 90% among Asians, less than 
20% among Caucasians and African-Americans. The ADH3 also exhibits a genetic 
polymorphism which results in the ADH3*2 allele that codes for 50% activity compared to 
the wild type. The ADH3*2 allele is due to the transitions Arg271Glu and Ile349Val [7]. The 
ADH3*2 allele is thought to be protective since it results in the reduced production of 
acetaldehyde, which is the toxic intermediate in alcohol consumption. Most of the 
acetaldehyde generated during alcohol metabolism is oxidized to acetate by the mitochondrial 
aldehyde dehydrogenase (ALDH2) a tetrameric protein. The gene for this enzyme is located 
on chromosome 12q24.2 where a single base pair difference in exon 12 (G→A) results in the 
substitution of glutamine at position 487 by a lysine, a change that leads to a catalytically 
inactive enzyme variant ALDH2*2 [8,9]. Human ALDH2 deficiency is the strongest genetic 
factor that influences the risk for alcohol related problems [10]. This mutant allele, which has 
mostly been reported among Asians at frequencies of approximately 50%, is a risk factor for 
upper aerodigestive tract cancers [11]. Experimental studies have supported the hypothesis 
that ethanol per se is not carcinogenic but under certain conditions it could act as a co-
carcinogen and/or a tumor promoter [12]. The metabolism of ethanol leads to generation of 
acetaldehyde and its production or degradation is modulated due to functional 
polymorphisms of the genes coding for the enzymes. Evidence has accumulated that 
acetaldehyde, which is a highly reactive molecule that can form adducts with proteins and 
nucleic acids is predominantly responsible for alcohol-associated carcinogenesis [13]. The 
occurrence of genetically determined atypical forms of ADH and ALDH2 has been reported 
in many populations and the contribution of this polymorphism to oesophageal cancer has 
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been described [14], however how enzyme polymorphisms influence individual cancer 
susceptibility is a new area of research [15].  
The objective of this study was to characterize the genetic differences in alcohol metabolizing 
enzymes (ADH and ALDH2) among Sudanese oesophageal cancer patients in comparison to 
healthy controls using single nucleotide polymorphisms (SNPs) as molecular markers and to 
report the frequency of the different alleles of ADH and ALDH2 in Sudanese.  
2. Materials and Methods: 
2.1. Subjects 
One hundred and thirty four (n=134) oesophageal cancer patients who underwent 
oesophagoscopy at the National Centre of Gastrointestinal and Liver Diseases, Ibn Sina 
Hospital and Khartoum Teaching Hospital and two hundred and thirty three (n=233) healthy 
Sudanese volunteers were studied during the period (2001 -2005). All patients and controls 
were included after a verbal informed consent. All the subjects completed a structured 
questionnaire which contained demographic information, alcohol consumption status and 
tobacco smoking habits. The diagnosis of oesophageal cancer was based on endoscopy as 
well as on histopathology examination of biopsies or resected specimens. Five ml venous 
blood samples were collected in EDTA coated tubes for DNA extraction. The protocol for the 
study was approved by the Medical & Health Studies Board of the Faculty of Medicine, 
University of Khartoum. 
2.2. DNA extraction and PCR amplification 
 Genomic DNA was extracted from the blood using salting-out method (routinely used in our 
laboratory). The DNA yield was determined spectrophotometrically. Primers were designed 
using the published data for sequences and were synthesized in a Beckman 1000A DNA 
synthesizer at the Medical School, University of Cape Town. For PCR amplification 100 ng 
of genomic DNA was mixed with a PCR mixture containing 1X Taq polymerase buffer, 0.2 
mM of each dNTPs, 1.5 µM of MgCl2, 50 pmol of each of the appropriate primers and 1u of 
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GoTaq polymerase (Promega, USA) in 25 µl total volume. ADH and ALDH2 genotyping was 
performed by restriction-fragment length polymorphism analysis (RFLPs) according to the 
methods of Xu et al. [9] and Wu et al [16] respectively. 
2.3. Genotyping for the ADH2*2 allele 
Fifteen µl of the PCR product was digested at 55˚C for two hours with Mae III enzyme 
(Roche Diagnostic, Germany). Aliquots were electrophoresed on 3% agarose gels, DNA 
molecular marker and an undigested fragment were run on every gel; bands were visualized 
under UV light. The variant ADH2*2 allele contains a restriction site for Mae III due to a 
SNP (G→A) transition in exon 3, this recognition site is absent in the wild type allele. 
Genotyping of the ADH2*3 allele 
The PCR amplified exon 9 of ADH2 gene, (15 µl) was digested with ALwN I enzyme 
(Biolabs, New England, UK) at 37˚C for two hours. Aliquots were electrophoresed on 2.5% 
agarose gels and bands were visualized and photographed (Figure I).  
Detection of the ADH3*2 allele 
After PCR amplification, 15 µl of the product was digested with Ssp I enzyme (Fermentas, 
Life Science) at 37˚C overnight. Aliquots were electrophoresed on 2.5% agarose gels. The 
normal ADH3*1 allele contains a restriction site for SspI, which is not present in the mutant 
ADH3*2 allele due to a SNP in exon 8 (A→G) transition. The amplified product is 130 bp; it 
is cut by the enzyme into 67 bp and 63 bp fragments. Subjects were classified as a normal 
homozygote ADH3*1/*1, a heterozygote ADH3*1/*2, and a mutant homozygote 
ADH3*2/*2. 
Genotyping of the ALDH2*2 allele in exon 12  
For the detection of ALDH2*2 allele, 15 µl of the PCR product were digested with MboII at 
37˚C overnight and then subjected to electrophoresis on 12% small polyacrylamide gel, the 
gel was then stained for 10 min with (300 ml 1XTBE and 10 µl ethidium bromide). The 
normal ALDH2*1 allele contains a restriction site for Mbo II, which is absent in the mutant 
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ALDH2*2 due to a SNP (G→A). 
2.4. Quality control 
 
DNA extraction was done in different times. PCR amplification and genotyping of the 
different samples were conducted blindly.  A quality control sample as well as a blank control 
(without DNA template) was used on every PCR operation. A random selection of 10% of all 
the samples was repeated for genotyping and no discrepancies were discovered. Two 
independent readers interpreted the gel photographs. 
2.5. Statistical analysis 
Data was analyzed using computer software SPSS for Windows (version 7.5). Statistical 
differences between mean values of the two groups were evaluated by using the chi-square 
statistics and logistic regression analysis to compare genetic polymorphisms in ADH2, ADH3 
and ALDH2 between patients and controls. A 5% level of significance was used in the 
analysis. The odds-ratio was estimated by the logistic regression model, assuming 95% as the 
confidence interval (CI).  
3. Results  
This is a case-control study comprising 134 patients with oesophageal cancer and 
healthy controls (n= 233 volunteers). Table I shows the demographic characteristics of the 
patients and controls. The mean age of the patients was 56.41 years and 47.87 years for the 
controls. The male/female ratio was 1.06:1. Most of the patients (68%) as well as the controls 
(61%) were of the Afro-Asiatic linguistic group. Both alcohol intake and smoking are 
significant risk factors for OC, (AOR= 3.3, P= 0.01) and (AOR= 2.23, P= 0.01) respectively. 
However, a considerable number of controls (32%) did not disclose whether they consume 
alcohol, neither did women confesse to be cigarette smokers. However, the overall 
frequencies of smokers and alcohol consumers were low in both patient and control groups. 
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All tobacco smokers and alcohol consumers were males. Histological examination of the 
patient samples showed that 75% of OC was squamous cell carcinoma and 14 % was 
Adenocarcinoma.  
Table II shows the genotype distributions and allele frequencies of ADH2, ADH3 and 
ALDH2 genes among the study subjects. The distribution of the wild-type, the heterozygous 
and the homozygous mutant genotypes of ADH2, ADH3 and ALDH2 were similar in patients 
and controls. There were no significant differences in the frequency distributions of the 
variant ADH2*2, ADH2*3, ADH3*2 and ALDH2*2 alleles between oesophageal cancer 
patients and healthy controls. The polymorphisms we studied featured genetically determined 
characteristics and should therefore remain unchanged with age, the age distribution would 
have no effect on the genotype frequency of subjects. Among the controls, the polymorphic 
alleles, ADH2*2, ADH2*3, ADH3*2 and ALDH2*2 occurred at frequencies 6%, 6%, 25% 
and 0% respectively. All genotype distributions of ADH and ALDH2 alleles fitted the Hardy-
Weinberg equilibrium.  
 
ADH2 gene polymorphism 
 For the polymorphic locus in exon 3, the allele frequencies of the normal ADH2*1 and 
the mutant ADH2*2 genotypes were similar in oesophageal cancer patients and controls 
(Table II). Concerning the different linguistic groups the Afro-Asiatic, the Nilo-Saharans and 
the Niger-Kordofanians, they had nearly equal frequencies of the mutant ADH2*2 in both 
patients (25, 31, 25) and controls (28, 22, 19 respectively) shown in Table III. 
ADH3 gene polymorphism 
The frequencies of the highly active ADH3*1 and the low activity ADH3*2 allele were 
similar in oesophageal cancer patients and controls (Table II). For the different linguistic 
groups, the Afro-Asiatic, the Nilo-Saharans and the Niger-Kordofanians had nearly equal 
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frequencies of the active ADH3*1 allele in patients (96, 95, 94) and in the control group (94, 
91, 98 respectively), Table III. 
ALDH2 gene polymorphism 
Figure II, shows the PAGE of ALDH2 gene (exon 12) digested with MboII, the use of 
PCR-RFLP method revealed that 0.4% of patients and none (0.0%) of the controls had the 
mutant ALDH2*2 allele (Table II). In the patients the variant allele was found only in the 
Afro-Asiatic group. The homozygous ALDH2*2/*2 genotype was not observed in any of the 
subjects in this study. All of the different linguistic groups in both patients and controls had 
equal ALDH2 allele frequencies, presented in (Table III). 
 
 
 
 
                                               M     1     2     3     4    un    
  
 
 
Figure I: ADH2 RFLP using Alwn I restriction enzyme: M = molecular weight marker (Marker 
VIII, Roche), (1= mutant, 2= mutant, 3= mutant, 4= heterozygous, un = uncut sample (202 bp). 
 
                                                
 
 
                                           M  un  1   2   3   4   5    6   7  8   he   
 
 
Figure II: ALDH2 RFLP using Mbo II restriction enzyme: M= molecular weight marker 
(Marker VIII, Roche) un = uncut sample (91 bp), 1 - 8 wild type (55, 26 and 10 bp), he = 
mutant heterozygous (65, 55, 26 bp). 
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4. Discussion 
There are many risk factors associated with the development of oesophageal cancer with each 
factor varying between different geographical areas. Within Sudan, oesophageal cancer is 
more prevalent in the North than in the South [17] and is strongly associated with the habit of 
placing tobacco under the tongue and alcohol consumption [18]. This is a case-control study 
comprising 134 patients with oesophageal cancer and (n= 233) healthy controls and is the 
first study in Sudan to investigate the correlation between polymorphisms of alcohol-
metabolizing enzymes and risk of oesophageal cancer. Most of the patients were the 
linguistic group of Afro-Asiatic origin similar to the controls. Although the study is hospital 
based there is limited role for selection bias because almost all suspected OC cases were 
referred only to the participating hospitals, therefore only few cases were missed. However, 
only those patients being able to travel to Khartoum were included in this study. Concerning 
their residence 76% of our patients are rural residents where life style patterns are relatively 
simple because of limited food choices. The low socioeconomic status and the poor nutrition 
of our patients may play role in the causation of OC in Sudan.  In this study patients and 
controls were similar with respect to female and male ratio (52% male in patients and 48% in 
controls). However, the age was not matched as there was a significant difference between 
the mean age of patients (56.41 years) compared with the controls (47.87 years) and this 
indicated that our patients are older than the controls. The study showed that the disease is 
equally prevalent in females and males and this is almost similar with the reported ratio by 
RICK (1:1.3) male/female. The observation of equal risks among males and females in our 
study is supported by the reported oesophageal cancer in Sudan having a relative female 
preponderance [17]. These Sudanese results differ from what is reported in the rest of the 
world being 4:1 male preponderance [2]. There are many risk factors for the development of 
OC with each factor varying between different geographical areas. Alcohol drinking is a 
major risk factor for oesophageal cancer and its impact may be modulated by levels of ADH 
and ALDH2 enzymes. Alcohol is principally metabolized to acetaldehyde which is eventually 
converted to acetate through the actions of enzymes belonging to the alcohol dehydrogenase 
(ADH) and aldehyde dehydrogenase (ALDH2) families. Acetaldehyde is a confirmed 
carcinogen thus its accumulation because of variability in the expression of ADH and 
ALDH2 enzymes due to genetic polymorphisms, could lead to increased susceptibility to 
oesophageal cancer. While a lot of studies have investigated the effects of polymorphisms in 
these genes, very little is known about their role in oesophageal cancer susceptibility among 
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especially indigenous Africans. In this study, the contribution of this polymorphism to 
oesophageal cancer risk has been investigated in Sudanese OC patients and unrelated healthy 
controls using polymerase chain reaction/ restriction fragment length polymorphism analysis 
(PCR/RFLP). We found that the frequencies of the variant ADH2*2 allele among patients 
and controls (5% and 6%, respectively) are higher than those reported among Caucasians and 
Xhosa speaking South Africans (Dandara et al., personal communication) but much less than 
the reported among Asians (up to 55%)  [19]. ADH2*2 which is associated with up to 100 
times more activity compared to the normal ADH2*1, can result in the fast accumulation of 
acetaldehyde. However acetaldehyde produces unpleasant effects resulting in carriers of such 
genotype avoiding alcohol consumption. In this study the ADH2*2 allele was not associated 
with increased risk of oesophageal cancer and this could have been due to carriers of this 
allele not tolerating alcohol. The study also showed that the frequencies of the variant 
ALDH2*2 allele in oesophageal cancer patients and controls were comparable with the 
reported value for the African [20]. The homozygous ALDH2*2/*2 genotype was not 
observed in any of the subjects in this study. Our results showed no significant differences in 
the frequency distribution of ADH2*2, ADH2*3, ADH3*2 and ALDH2*2 alleles between 
oesophageal cancer patients and healthy controls. Among the controls, the polymorphic 
alleles in the alcohol metabolizing genes, ADH2*2, ADH2*3, ADH3*2 and ALDH2*2 
occurred at frequencies 6%, 6%, 25% and 0% respectively. In conclusion, this study has 
shown for the first time the distribution of ADH2, ADH3 and ALDH2 genotypes in the 
Sudanese population. More studies are needed that would investigate polymorphisms in the 
genes that encode for enzymes metabolizing constituents of tobacco smoke since the use of 
tobacco is becoming much more common among Sudanese subjects. The fact that these 
results did not show an association between OC and the polymorphisms in genes controlling 
alcohol metabolism can be associated to the patients and controls were from the whole 
Sudanese population without targeting specific ethnic background, as well there were not 
enough numbers to stratify these into different ethnic groups and hence this lack of 
concordance. The incidence of OC is still very low in Sudan as a whole compared to other 
nations. However there is a clear tendency that people from North-eastern Sudan (mostly Bija 
ethnic group) show high prevalence of OC and factors pertaining to this must be sought in 
future studies. Another factor which must be considered is that alcohol consumption in a 
mostly Muslim community is a social stigma and therefore easily denied making the number 
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of unknowns significantly high. This is true also for smoking among women which is 
culturally unwelcomed. 
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Table I: Demographic characteristics of the Sudanese oesophageal cancer patients and 
controls 
 
    Cases                   Controls 
Characteristic   n (freq)       n (freq)           AOR (95% CI) p-value 
 
Age (years) 
 
<60     64 (48)              186 (80)  
>60    70(52)                47 (20) 
Total                                      134               233 
 
Sex 
 
Female             65 (49)               121(52)  
Male              69 (51)     112(48)                1.3(0.82-1.9) 0.28    
Total                                     134                233 
 
Linguistic group 
 
Afro-Asiatic                             91(68)                140(61)  
Nilo-Saharan                           33 (25)                 63(27)                    0.44(0.19-1.01) 0.052     
Niger-kordofanian                    8 (6)                   28(12)                    0.81(0.49-1.32) 0.4     
Unknown                                  2 (2)                     2(0)                      1.54(0.21-1.7) 11.1     
Total                                      134                 233 
 
Smoking 
 
No    102 (76)      141 (60)   
Yes      29 (22)        18 (8)              2.23(1.17-4.2) 0.01     
Unknown                                    3(2)                     74 (32)                  0.05(0.18-0.18) 0.00     
Total                                       134                    233 
 
Alcohol consumption 
   
No    113 (84)       152 (65)               1.00 
Yes      17 (13)          7 (3)               3.3(1.3-8.1) 0.01     
Unknown                                    4 (3)                 74(32)                    0.07 (0.03-0.2) 0.00     
Total                                       134                   233 
 
Histopathological types 
 
SCC                                         101(75) 
ADC                                          18(14) 
Others                                        15(11) 
Total                                        134                    
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Table II:  Distribution of the ADH and ALDH2 genotypes in the Sudanese subjects 
 
 
          Patients         Controls 
Genotype         n (freq)           n (freq)                 AOR (95% CI) p-value 
 
ADH2 
 
ADH2*1/*1        115(92)                 188 (89)           
ADH2*1/*2           8 (6)                     18 (9)                 0.73(0.31-1.7) 0.47     
ADH2*2/*2           2 (2)                       4 (2)                 0.82(0.15-4.5) 0.82  
 Total                                125                         210    
  
ADH2     
 
ADH2*1/*1        97(90)                  164 (90)           
ADH2*1/*3        10 (9)                     17 (9)               
ADH2*3/*3          1 (1)                       2 (1)   
Total                                108                         183       
 
ADH3 
 
ADH3*1/*1         67 (52)               118(54)           
ADH3*1/*2         55 (43)                 89(41)                1.09(0.69-1.7) 0.71         
ADH3*2/*2           6 (5)                   10(5)                  1.06(0.37-3.04) 0.91  
 Total                                128                         217        
 
ALDH2                                   
ALDH2*1/*1                   121(99)               213 (100)             
ALDH2*1/*2       1.0 (1)                 0.0 (0.0)                 0.73(0.31-1.7) 0.47                       
ALDH2*2/*2                    0.0 (0.0)              0.0 (0.0)                0.73(0.31-1.7) 0.47  
Total                                122                         213 
         
Allele frequencies 
 
ADH2*1                       95%                   94%   
ADH2*2   5%                     6% 
ADH2*1                       95%                   94%   
ADH2*3   6%                    6% 
ADH3*1                                74%                  75%    
ADH3*2             26%                  25% 
ALDH2*1             99.6%              100% 
ALDH2*2                              0.4%  0.0% 
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Table III: Allele frequencies of the different genes among the study linguistic groups 
 
 
       Patients (freq)                                   Controls (freq) 
 
Allele                         AA         NS         NK                         AA          NS       NK 
         
ADH2*1                    75           69           75                          72           78          82                 
ADH2*2           25           31           25                          28           22          19 
     
ADH3*1           96           95           94                          94           91          98       
ADH3*2             4             5             6                            6             9            2   
                             
ALDH2*1                  99          100          100                      100          100        100  
ALDH2*2                  0.6          0.0           0.0                       0.0          0.0         0.0 
 
AA = Afro-Asiatic  
NS = Nilo-Saharan                            
NK=Niger-Kordofanian   
 
 
 
                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 105
 
Genetic polymorphisms of CYP3A5, GSTM1 and GSTT1 as a risk modifier of 
oesophageal cancer in Sudan 
 
H. B. Eltahir1, C. Dandara2, M. I. Parker2, M. E. Ahmed3, S. S. Fedail4, A. O. Mohamed5 
 
1Department of Biochemistry, Faculty of Medicine, University of El Imam El Mahdi, Sudan 
2UCT/MRC-Oesophageal Cancer Research Group, Division of Medical Biochemistry, Institute of 
Infectious Disease and Molecular Medicine (IIDMM), Faculty of Health Sciences, University of Cape 
Town, South Africa. 
3Department of Surgery, Faculty of Medicine, University of Khartoum, Sudan 
4National Center of Gastrointestinal and Liver Diseases, Ibn Sina Hospital, Khartoum, Sudan.  
5Department of Biochemistry, Faculty of Medicine, University of Khartoum, Sudan 
 
Abstract:  
 
Most of the environmental toxins are metabolically oxidized by phase I enzymes such as 
cytochrome P-450s (CYPs) and some of the intermediates generated during this process are 
genotoxic compounds. Detoxification and excretion of these reactive intermediates requires 
phase II enzymes such as glutathione S-transferases (GSTs). Some individuals may be at 
increased risk for oesophageal cancer due to inability to metabolize or detoxify certain 
environmental carcinogens. CYP3A5 is one of the major CYPs expressed in oesophageal 
mucosa and exhibits genetic polymorhisms. Homozygous deletions of GSTM1 and GSTT1 
genes is a common phenomenon We conducted a hospital-based case-control study in Sudan 
to investigate the role of genetic variants of CYP3A5, GSTM1 and GSTT1 alone or in 
combination in modification of oesophageal cancer risk. A total of 113 cases and 203 healthy 
unrelated controls were included. Life style information and detailed smoking history were 
obtained using standard questionnaire. Genotyping was performed by PCR/RFLP analysis. 
We used multivariant logistic regression analysis to estimate oesophageal cancer risk 
associated with CYP3A5, GSTM1 and GSTT1 polymorphisms. Our results show that while 
there is no significant correlation between CYP3A5 polymorphism and oesophageal cancer, 
the GSTM1 and GSTT1 null-genotypes appear to be associated with increased risk among 
the Sudanese. 
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Introduction 
 
Cancer of the oesophagus has been reported as the ninth most common malignancy 
and ranks as the sixth most frequent cause of cancer death in the world. It also constitutes 7% 
of all gastrointestinal cancers [1]. The burden of oesophageal cancer is huge and the 5-year 
survival rate is less than 10% [2], this is due to a combination of factors including late 
presentation, associated cardiac and respiratory diseases and the technical difficulties of 
resectional surgery [3]. Globally the incidence of oesophageal cancer varies significantly by 
geographic regions, race and gender. High incidence areas in Africa include several East 
African countries (South Africa, Mozambique, Zimbabwe, Tanzania, Kenya and Uganda) [4]. 
In Sudan, for the last 5 years, data on cases of oesophageal cancer seen in Radiation and 
Isotopes Center in Khartoum (RICK 2001-2005) revealed that there is a clear increase of the 
disease in the north -eastern part of the country and that oesophageal cancer is the ninth most 
common cancer with an incident of 5.7 % of the total malignancies. Nearly 200 people are 
diagnosed each year and the disease is predominant in females, in particular among females 
in the age range 45-55 years and the majority of patients presenting with advanced disease.   
Most carcinogens that humans are exposed to through diet, drugs and lifestyles such as 
smoking, are metabolically oxidized by a group of enzymes classified as phase I enzymes and 
include cytochrome P450s (CYPs). The resultant products of metabolism are reactive and 
readily react or bind to cell macromolecules including DNA and proteins forming adducts. 
Sometimes this interaction is a recipe for cancer initiation.  However, the human body has 
another group of enzymes that is responsible for the removal of the reactive intermediates 
generated from phase I metabolism and is referred to as phase II. They accomplish their role 
by conjugating the reactive intermediates thereby facilitating their removal from the body 
through mostly the mercapturic acid pathway. The phase II group of enzymes include such 
families of enzymes as glutathione s-transferases (GSTs), N-acetyltrasferases (NATs) and 
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sulphotransferases [5]. An imbalance between phase I and phase II enzymes may contribute 
to the development cancer. 
Among humans there are three main CYP families that are involved in xenobiotic 
metabolism and these are the CYP1, 2, and 3 families [6]. The CYP3A isozymes constitute 
the largest portion of cytochrome P450 protein in the liver and small intestine and are 
responsible for the metabolism of more than 50% of all currently known drugs. There are 
four members of the subfamily 3A (3A4, 3A5, 3A7, 3A43) all of which reside in a 231-kb 
chromosomal region 7q21.1 [7]. CYP3A5 may represent up to 50% of total CYP3A in 
individuals expressing the protein [8]. CYP3A5 is the major cytochrome enzyme expressed 
in oesophageal mucosa where it metabolises many potentially carcinogenic compounds. The 
enzyme exhibits genetic polymorphism as it is expressed in some individuals with an ethnic 
difference in the distribution of the non-expressors [9]. 
Glutathione S-transferases, (GSTs) are a supergene family of enzymes involved in the 
biotransformation of xenobiotics. They play an important role in the prevention of cancer by 
detoxifying (deactivating) numerous potential toxins [10]. Of the seven families of GST, the 
major xenobiotic metabolising isoforms are found in the GST-Mu, Theta and Pi families. 
While GSTM1 is mostly expressed in the oesophagus, GSTT1 is abundantly expressed in 
oesophageal mucosa. Both are involved in the detoxification of reactive epoxide 
intermediates generated from the activation of polycyclic aromatic hydrocarbons and other 
mutagens by CYP enzymes [11]. Homozygous deletions of GSTM1 and GSTT1 genes are 
frequently reported and result in lack of enzyme activity. Frequencies of homozygous 
GSTM1 deletion (GSTM1 null) vary from as low as 15% to as high as 90% among different 
world populations [12].  The percentage of individuals with the null genotype is higher in 
Caucasian and Asian populations (50%) than it is among people of African descent [13]. 
GSTT1 gene which is located on chromosome 1, exhibits genetic polymorphism and the 
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frequencies of the GSTT1 null allele differs in different ethnic groups [14,15] For example, 
homozygous deletion of the GSTT1 gene was reported in 24% to 38% of people from 
African origin [16].  The GSTM1 and GSTT1 gene polymorphisms could be important in 
human carcinogenesis and have been shown to be associated with increased risk of many 
cancers [17] including lung, nasopharyngeal, breast, uortheral, prostate cancer, lymphocytic 
leukemia and squamous displasia of the oesophagus. [18]. 
The objective of this study was to identify genetic polymorphisms of xenobiotic-
metabolizing enzymes in relation to oesophageal cancer among Sudanese subjects. 
2. Materials and Methods: 
2.1. Subjects 
One hundred and thirteen (n=113) oesophageal cancer patients who underwent 
oesophagoscopy at the National Centre of Gastrointestinal and Liver Diseases, Ibn Sina 
Hospital and Khartoum Teaching Hospital and 203 healthy Sudanese volunteers were studied 
during the period (2001 -2005). All patients and controls were included after verbal informed 
consent and the completion of a structured questionnaire which contained information on 
such things as alcohol consumption status and tobacco smoking habits. The diagnosis of 
oesophageal cancer was based on endoscopy as well as on histopathology examination of 
biopsies or resected specimens. The protocol for the study was approved by the Medical & 
Health Studies Board of the Faculty of Medicine, University of Khartoum. 
2.2. Sampling, DNA extraction and PCR 
Five ml venous blood samples were collected in EDTA coated tubes for DNA 
extraction. Genomic DNA was extracted from the blood using salting-out method (routinely 
used in our laboratory). The DNA yield was determined spectrophotometrically. Primers 
were designed using the published data for sequences and were synthesized in a Beckman 
1000A DNA synthesizer at the Medical School, University of Cape Town.  The PCR 
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amplification was performed in a 25 µl total mixture that contained 1X buffer, 0.2 mM 
dNTPs, 1.5 µM MgCl2, 50 pmol of each primer, 100 ng of genomic DNA, and 1u of Gotaq 
polymerase using reagent kits from Promega and a programmable thermocycler (PCRexpress 
UK).  
2.3. PCR/RFLP analysis of CYP3A5 polymorphism using Ssp I restriction enzyme:  
CYP 3A5*3 allele was investigated according to the method of [Schaik et al]. [8]. 
Primers for CYP3A5*3 (forward) 5’-CATCAGTTAGTAGACAGATGA-3’ and (forward) 
(reversed) 5’-GGTCCAAACAGGGAAGAAATA-3’ were used. Initial denaturation was 
performed at 94˚C for 2 min followed by 30 thermal cycles consisting of denaturation for 
1min at 94˚C, annealing for 30 seconds at 55 ˚C, extension for 1 min at 72˚C and final 
extension for 7 min at 72˚C. The PCR products were digested with Ssp I enzyme (Fermentas, 
Life science) at 37˚C for two hours and subjected to electrophoresis on 3% agarose gels, 
bands were visualized with an ultraviolet transilluminator. The amplified fragment is 293-bp, 
the normal wild-type allele has two cutting sites, the enzyme cut it into 148, 125, 20-bp 
fragments. The variant allele has only one cutting site which is different from that of the 
normal allele and the enzyme cut it into 168 and 125 bp fragments.  
  2.4. Detection of the GSTM1 and GSTT1 null genotypes  
For the detection of GSTM1 and GSTT1 polymorphisms, we used the polymerase 
chain reaction (PCR) methodology according to the method of Arnad et al [19] with the 
following oligonucleotide primers in the same reaction tube, primers to the region containing 
the deletion in the GSTM1 gene were, (forward) 5’-GAA CTC CCC TGA AAA GCT AAA 
GC-3’ and (reversed)  5’-GTT GGG CTC AAA TAT ACG GTG G-3’, the  primers to the 
region containing the deletion in the GSTT1 gene, (forward) 5’-TTC CTT ACT GGT CCT 
CAC ATC TC-3’ and (reversed) 5’-TCA CCG GAT CAT GGC CAG CA- 3’ which  
corresponded to exon 5 and 6, and intron 5 [20],  the third set is for amplification of human 
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albumin gene as an internal control in all samples using the primers,  (forward) 5’GCC CTC 
TGC TAA CAA GTC CTA-3’ and (reversed)  5’-GCC CTA AAA AGA AAA TCC CCA 
ATC- 3’. Initial denaturation was performed at 94˚C for 5min followed by 35 thermal cycles 
consisting of denaturation for 1 min at 94˚C, annealing for 1 min at 60˚C, extension for 1min 
at 72˚C and final extension for 5mins at 72˚C.  PCR products were electrophoresed on 2% 
agarose gels. A 459-bp fragment was amplified with the GSTT1 primers and a 215-bp 
fragment was amplified with GSTM1 primers. The absence of the specific product of 
GSTM1 or GSTT1 in the presence of HAS gene product (350 bp) indicated the 
corresponding null genotype. Although this technique does not distinguish between 
homozygotes and heterozygotes of the positive genotypes, it identifies conclusively the null-
genotypes. 
 
2.5. Quality control 
 
DNA extraction was done in different times. PCR amplification and genotyping of the 
different samples were conducted blindly.  A quality control sample as well as a blank control 
(without DNA template) was used on every PCR operation. A random selection of 10% of all 
the samples was repeated for genotyping and no discrepancies were discovered. Two 
independent readers interpreted the gel photographs. 
2.6. Statistical analysis 
 
Data was analyzed using computer software SPSS for Windows (version 7.5). 
Statistical differences between mean values of the two groups were evaluated by using the 
chi-square statistics and logistic regression analysis to compare genetic polymorphisms in 
CYP3A5, GSTM1 and GSTT1 between the cases and controls. A 5% level of significance 
was used in the analysis. The odds-ratio was estimated by the logistic regression model, 
assuming 95% as the confidence interval (CI).  
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3. Results: 
This is a case-control study comprising 113 patients with oesophageal cancer and controls 
(n= 203 healthy volenteers). Older age was associated with increased risk of oesophageal 
cancer. The frequencies of smokers and alcohol consumers were low in both patients and 
controls and all tobacco smokers and alcohol consumers were males. However, a 
considerable number of controls did not disclose their alcohol consumption, neither did 
women confessed to be cigarette smokers.   
The allele frequencies and genotype distributions of CYP3A5, GSTM1 and GSTT1 
among the study subjects are shown in (Table 1). All genotype distributions of CYP3A5, 
GSTM1 and GSTT1 alleles fitted the Hardy-Weinberg equilibrium. 
CYP3A5 gene polymorphism 
Figure I, shows the RFLP pattern of the different fragments of CYP3A5 gene. There were 
more homozygous CYP3A5*3/*3 carriers among patients compared to controls although this 
distribution was not statistically significant. There was no significant difference in the 
frequency distribution of the mutant CYP3A5*3 allele between oesophageal cancer patients 
(62%) and healthy controls (62%), (Table I). The frequencies of the mutant CYP3A5*3 allele 
among the different linguistic groups are shown in (Table II). There were however 
differences in the distribution of the CYP3A5*3 allele in different linguistic groups, being 
highest among the Afro-Asiatics, followed by Nilo-Saharan and (52%) and the Niger-
Kordofanian group (29%), Table II. 
GSTM1 and GSTT1- null genotypes 
Figure II shows the PCR-based electrophoresis of GSTM1 and GSTT1 on 2.5% 
agarose gel. The frequencies of GSTM1 and GSTT1-null genotypes were higher in 
oesophageal cancer patients (53% and 82%, respectively) compared to the control group 
(39% and 61%, respectively). Both the homozygous GSTM1 and GSTT1 genotypes were 
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associated with increased risk of oesophageal cancer (OR 1.8 and OR 2.9, respectively) 
(Table I). Individuals with the null genotypes for both M1 and T1 (48%) are at a significant 
higher risk for developing oesophageal cancer than those with both genes present (12%). 
Among the oesophageal cancer patients, the Afro-Asiatic and the Nilo-Saharan groups had 
the highest frequencies of the homozygous GSTM1*0 genotype (56% and 48%, 
respectively), whereas, the frequencies was very low among the Niger-Kordofanians (33%). 
For the GSTT1*0 allele, the Afro-Asiatic and the Nilo-Saharans had the highest frequencies 
of the deletion among patients (81% and 86%, respectively) compared to the controls (56% 
and 63%, respectively). however, the Niger-Kordofanian group had equal frequencies in 
patients and controls (83% & 81%).  
                                                             M  1  2  3  4  5   6 
 
 
 
     Figure I: CYP3A5 RFLP using Ssp I restriction enzyme: M = molecular weight marker, 2 
= wild type (148, 125, 20 bp), 1,5 = heterozygous,  3,4,6 =  mutant (168, 125 bp). 
 
 
 
                                                      M     1     2    3      B    4    5        
 
 
Figure II: Agarose gel electrophoresis results of the PCR products of GSTM1 and GSTT1 
and the internal control: M = molecular weight marker (Marker VIII, Roche), B = blank 
(negative control); 1 = positive for     both GSTM1 (215bp) and GSTT1 (459bp), 2 = negative 
for GSTM1 and positive for GSTT1, 3 = positive for GSTM1 and negative for GSTT1, 4,5 = 
negative for both GSTM1 and GSTT1 but positive for the internal control (350bp). 
 
 
 
168bp 
125bp 
 
 
459bp 
350bp 
215bp 
 113
4. Discussion 
Xenobiotic-metabolizing enzymes are present in most epithelial tissues of the human 
gastrointestinal tract where they provide in situ protection from toxic or carcinogenic food 
components. Differences in biotransformation activities may provide protection from certain 
xenobiotic or increase toxicity of others. Individual susceptibility to oesophageal cancer may 
be partly due to genetic differences in genes controlling the metabolic balance between the 
activation (by CYPs) and detoxification (by GSTs or SULTs) of procarcinogens in the 
environment. In this study we investigated a potential correlation between gene 
polymorphisms in phase I (CYP3A5) and phase II (GSTM1, GSTT1 and SULT1A1) alone or 
in combination and OC risk. The study is the first in Sudan to investigate a correlation 
between polymorphism of xenobiotic-metabolizing enzymes and the risk of oesophageal 
cancer. We genotyped 112 patients with oesophageal cancer and the results were compared 
with those optained from 213 healthy controls using PCR-based RFLP analysis. Our finding 
showed no significant difference in the frequency distribution of the mutant CYP3A5*3 
alleles between oesophageal cancer cases (62%) and controls (62%). There is no significant 
correlation between genetic polymorphism in CYP3A5 and oesophageal cancer. One of the 
reasons for a non-correlation of CYP3A5 polymorphism with oesophageal cancer might be 
the extreme racial mixing in the Sudanese population. It is possible that different variants 
may be genetically linked with different mutations. Therefore, care must be taken when 
analyzing data from a population composed of subjects from different ethnic groups. 
The lack of an effective detoxification system might be a risk factor for oesophageal cancer. 
Indeed, the GST family catalyzes reactive carcinogenic intermediates that are produced 
through the metabolism of environmental toxins by CYP450s. GSTM1 and GSTT1 are 
polymorphic and are commonly absent in human population. This study showed that the 
frequencies of GSTM1 and GSTT1-null genotypes were higher in oesophageal cancer 
patients (53% & 82% respectively) than in the control group (39 & 61% respectively). There 
is a significant association between patients and control groups for GSTM1-null allele (p= 
0.02 and OR=1.8) and for GSTT1-null allele (p= 0.00 and OR=2.9). Interestingly the 
frequency of the GSTM1-null genotype in our control group (38.9%) is equal to that reported 
previously in Sudanese subjects in a study done by Tiemersma et al [20]. These results are in 
agreement with a study done by Nimura et al. [21] showed an association between GSTM1 
null genotype and oesophageal cancer. The influence of this polymorphism was already 
determined in other cancers such as oral and gastric and lung cancers [22,23,24], which lead 
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to the hypothes that a GSTM1 or GSTT1 null deletion contributes to the genesis of 
oesophageal cancer, this will lead to the hypothesis that a GSTM1 or GSTT1 null deletion 
contributes to the genesis of oesophageal cancer.  
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Table I: The distribution of CYP3A5, GSTM1 and GSTT1 genotypes and alleles among 
Sudanese patients and controls 
 
            Cases       Controls 
Characteristic            n (%)             n (%)            AOR (95% CI) p-value 
 
CYP3A5 genotype   
CYP3A5*1/*1                        25 (23)         37 (18)                            
CYP3A5*1/*3                        31 (29)         81 (40)             0.57 (0.29-1.1) 0.09                        
CYP3A5*3/*3                        52 (48)         87 (42)             0.88 (0.47-1.6) 0.7     
Total             108        205 
 
Allele frequencies 
 
CYP3A5*1                          81 (38) 155 (38) 1.00  
CYP3A5*3                        135 (62)            255 (62) 0.98 (0.70-1.39) 0.940 
Total    216   410 
 
GSTM1 genotype  
 
GSTM1*1                               53 (47)          124 (61)                                                          
GSTM1*0                60 (53)            79 (39)             1.8 (1.11-2.83) 0.02                                               
Total             113           203 
 
GSTT1 genotype  
 
GSTT1*1                                20 (18)             79 (40)                                                            
GSTT1*0                93 (82)           124 (61)          2.96 (1.7-5.2) 0.001   
Total             113            203                                                        
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Table II:  Distribution of the gene variants in linguistic groups among Sudanese subjects. 
 
       Patient                                               Controls  
 
Allele                       AA          NS           NK                AA              NS             NK 
          N (%)     N (%)      N (%) N (%)          N (%)    N (%) 
           
CYP3A5*3            62(70)       19 (52)    2 (29)           104 (63)      44 (63)     20 (56) 
  
GSTM1*0             44 (56)      14 (48)    2 (33)          46 (38)        18 (32)      14 (54) 
 
GSTT1*0              63 (81)      25 (86)    5 (83)            68 (56)       35 (63)     21 (81)   
 
 
 
AA = Afro-Asiatic  
NS = Nilo-Saharan                            
NK = Niger-Kordofanian   
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Abstract: 
 
Sulfonate conjugation is an important phase II reaction in the biotransformation. SULT1A1 
appears to be the principle human sulfotransferase involved in the elimination of most 
phenolic xenobiotics as well as bioactivation of several procarcinogens. Studies have 
demonstrated a large individual variation in the activity of SULT1A1, an individuals 
homozygotes for the SULT1A1*2 allele had only about 15% of the SULT activity and it may 
has the potential to influence individual susceptibility to chemical carcinogensis.  The 
purpose of this hospital-based case control study was to evaluate whether SULT1A1 (G638A) 
polymorphism causes Arg213His amino acid change is a risk factor for oesophageal cancer in 
Sudan. A total of 112 patients and 194 healthy controls were included. Life style information 
and detailed smoking history were obtained. Genomic DNA was isolated from peripheral 
blood lymphocytes and genotyping was performed using PCR/RFLP analysis. Our finding 
showed that the frequency of the SULT1A1*2 (His) allele was 18% in cases and 15% in 
controls. Multivariant logistic regression analysis showed no significant association between 
SULT1A1*2/*2 genotype and oesophageal cancer risk (OR=3.7, P= 3.7, CI= 0.33 - 41.5). We 
concluded that SULT1A1 (G638A) polymorphism is not a risk factor for oesophageal cancer 
in Sudan  
 
 
Keywords: oesophageal cancer, sulfotransferase 1A1, genetic polymorphism. 
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1. Introduction: 
Sulfotransferases (SULTs), a superfamily of multifunctional enzymes, catalyze sulfonate 
conjugation which is an important phase II reaction in the metabolism of numerous 
endogenous and exogenous compounds [1]. Sulfotransferases transfer the sulph moiety 
(sulfuryl group) from the cofactor 5-phosphoadenosine-3-phosphosulfate (PAPs) to 
nucleophillic group (hydroxyl or amino functional group) of an acceptor substrate; the 
products are adenosine 3, 5- diphosphate (PAP) and a sulfuric acid ester, respectively [2]. 
Sulfonation is generally considered as a detoxification mechanism that generates more water-
soluble and often less toxic metabolites. However, conjugation of certain compounds may 
produce electrophiles that react with DNA for adduct formation [3]. Eleven distinct 
xenobiotic-metabolizing sulfotransferases have been identified in humans encoded by ten 
different SULT genes; they are all soluble cytosolic proteins that differ in tissue distribution 
and substrate specificity [4,5]. Most of the human SULTs exist as homodimers and the 
monomeric subunits consist of 284 to 365 amino acid residues. Three SULT1A proteins 
occur in human tissues, 1A1, 1A2, 1A3, showing the same number of amino acid residues 
(295) and 93% to 96% sequence identity. All three SULT1A genes are mapped to 
chromosomal region 16p12.1–11.2 [5,6,7]. SULT1A1 is one of the most important members 
of human SULTs due to its extensive tissue distribution and highest expression level, it 
appears to be the principal SULT form involved in the detoxification of most phenolic 
xenobiotic as well as bioactivation of several procarcinogens such as hydroxyl arylamines, 
heterocyclic amines and polycyclic aromatic hydrocarbons (PAHs) [8]. Inherited differences 
in the enzymatic activity of SULTs are likely to influence the individual’s risk for cancer [9]. 
Studies have demonstrated a large individual variation in the activity of SULT1A1, which 
could be explained by the newly identified common single nucleotide polymorphism 
(G638A) transition in the coding region (exon7) of the SULT1A1 gene (referd to as 
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SULT1A1*2 allele). It results in an Arg to His substitution at codon 213 associated with 
reduced enzyme activity and thermal stability compared with that of SULT1A1*1 allele 
[6,8,10,11]. An individual homozygote for the SULT1A1*2 allele had only about 15% of the 
SULT activity in platelets of those with other genotypes [12]. This mutant allele occurs in 
relatively high but various frequencies in different ethnic populations, it was reported to be 
about 30%-35%, in Caucasians and about 27% in Africans and African-Americans [6,13]. 
The importance of SULT1A1 in biotransformation of carcinogens suggests that this 
polymorphic enzyme activity may have the potential to influence individual susceptibility to 
chemical carcinogensis. Several studies have shown that SULT1A1 polymorphisms may play 
some role in the development of cancers [14].  
In this report we have investigated the role of the variant allele SULT1A1*2 as a risk factor 
for development of oesophageal cancer in a Sudanese population.  
2. Materials and Methods: 
2.1. Subjects 
One hundred and twelve oesophageal cancer patients who underwent oesophagoscopy at the 
National Centre of Gastrointestinal and Liver Diseases, Ibn Sina Hospital and Khartoum 
Teaching Hospital and one hundred and ninety four healthy Sudanese volunteers were studied 
during the period (2001-2005). All patients and controls were included after a verbal 
informed consent; they all completed a structured questionnaire which contained information 
such things as alcohol consumption status and tobacco smoking habits. The diagnosis of 
oesophageal cancer was based on endoscopy as well as on histopathology examination of 
biopsies or resected specimens. The protocol for the study was approved by the Medical & 
Health Studies Board of the Faculty of Medicine, University of Khartoum. 
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2.2. Sample collection and DNA extraction 
Five ml venous blood samples were collected in EDTA coated for DNA extraction. Genomic 
DNA was isolated from the peripheral blood lymphocytes using salting-out method (routinely 
used in our laboratory) and the DNA yield was determined spectrophotometrically.  
2.3. PCR-based genotyping 
RFLP analysis of SLUT1A1 polymorphism in exon 7 using Hae II restriction 
enzyme:  
SULT1A1 alleles were investigated according to the method of Coughtrie et al [6]. The 
primers for SULT1A1 gene were designed using the published data for sequences and were 
synthesized in a Beckman 1000A DNA synthesizer at the Medical School, University of 
Cape Town, forward primer 5’-GTTGCCTCTGCAGGGTCTGGAGAG-3’ and reverse 
primer 5’-CCCAAACCCCCGTACTGGCCAGCACCC-3’. PCR amplification was 
performed in a 25 µl total mixture that contained 1X buffer, 0.2 mM dNTPs, 1.5 µM MgCl2, 
50 pmol of each primer, 100 ng of genomic DNA, and 1u of Gotaq polymerase using reagent 
kits from Promega, Initial denaturising was done at 94˚C for 2 min followed by 40 thermal 
cycles consisting of denaturation for1min at 94˚C, annealing for 30 seconds at 63˚C, 
extension for 30 seconds at 72˚C and final extension for 5 min at 72˚C using a programmable 
thermocycler (PCRexpress, UK). The PCR products were digested with Hae II enzyme 
(Promega) at 37˚C for six hours and subjected to electrophoresis on 3.5 % agarose gels and 
bands were visualized with an ultraviolet transilluminator. The amplification product is 333-
bp fragment. The wild-type SULT1A1*1 allele has a cutting site for Hae II, it is cut into 168 
and 165-bp fragments. The restriction site is not found in the variant SULT1A1*2 allele. The 
genotypes of SULT 1A1 were classified as a homozygote normal SULT1A1*1/*1, a 
heterozygote SULT1A1*1/*2 and a homozygote mutant SULT1A1*2/*2. 
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2.4. Quality control 
DNA extraction was done in different times. PCR amplification and genotyping of the 
different samples were conducted blindly.  A quality control sample as well as a blank control 
(without DNA template) was used on every PCR operation. Two independent readers 
interpreted the gel photographs. A random selection of 10% of all the samples was repeated 
for genotyping and no discrepancies were discovered.  
 
2.5. Statistical analysis 
Data was analyzed using computer software SPSS for Windows (version 7.5). Statistical 
differences between mean values of the two groups were evaluated by using the chi-square 
statistics and logistic regression analysis to compare genetic polymorphisms in SULT1A1 
gene between the cases and controls. A 5% level of significance was used in the analysis. The 
odds-ratio was estimated by the logistic regression model, assuming 95% as the confidence 
interval (CI).  
3. Results: 
This is a case-control study comprising 112 patients with oesophageal cancer and controls 
(n= 194 healthy volenteers). The mean age of the patients was 57.04 years and 48.07 years 
for the controls. The male/female ratio was 1:1.5. Most of the patients as well as the controls 
were of the Afro-Asiatic linguistic group. The frequencies of smokers and alcohol consumers 
were low in both patients and controls and all tobacco smokers were males. However, a 
considerable number of controls did not disclose their smoking (32%), neither did women 
confessed to be cigarette smokers.   
The allele frequencies and genotype distributions of SULT1A1 among the study subjects are 
shown in (Table I). All genotype distributions of SULT1A1 alleles fitted the Hardy-Weinberg 
equilibrium. The common SULT1A1*1 allele and the minor SULT1A1*2 allele occurred at 
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an equal frequencies in patients (82% and 16%) and in control subjects (85% and 15%). The 
genotype distributions of SULT1A1 were found to be SULT1A1*1/*1 (66%), 
SULT1A1*1/*2 (32%) and SULT1A1*2/*2  (2%) in patients compared with respective 
SULT1A1*1/*1 (70%), SULT1A1*1/*2  (29%) and SULT1A1*2/*2  (1%) in control 
subjects. All of the different linguistic groups in both patients and controls have equal 
SULT1A1 allele frequencies, presented in Table II. However, the Niger-Kordofanian group 
had slightly higher frequency of the mutant SULT1A1*2 among patients (29%) compared to 
controls (5%).  
4. Discussion  
SULT1A1 is an important phase II reaction in xenobiotic-metabolism. The frequency of the 
SULT1A1 gene showed a wide variation among different ethnic groups. Little is known of 
the role of SULT1A1 polymorphism in disease susceptibility and a few case control studies 
have been published with regard to the association between the SULT1A1 polymorphism and 
risk of certain cancers. In this study we investigated gene-environment interaction with 
polymorphism of SULT1A1 enzyme in terms of oesophageal cancer risk using PCR-based 
genotyping assay (PCR/RFLP). We hypothesized that the wild-type SULT1A1 allele protect 
against the risk of oesophageal cancer. Our data showed no significant difference in 
SULT1A1 allele distribution between cases and controls, the common SULT1A1*1, Arg213 
allele and the minor SULT1A1*2, His213 allele occurred at equal frequencies in patients 
(82.1% and 17.9%) and in control subjects (85.1% and 14.9% respectively). The frequency of 
the wild-type SULT1A1*1 allele was higher in Asiatic (Chinese and Japanese) than 
Caucasian (German, American, British) and African (Nigerian) populations [15]. Previous 
study in an African population (Nigerian) done by Coughtrie et al [6], showed that the 
frequency of SULT1A1*1 allele was 73% and that of SULT1A1*2 allele was 26.9%. Our 
findings revealed no associations between the SULT1A1 G638A gene polymorphism and 
oesophageal cancer risk.  Other results showed strong association between SULT1A1 
(G638A) genotype and the risk of oesophageal cancer risk in a Chinese population reported 
by Wu et al [16]. Our study did not find any evidence for interaction of SULT1A1 with 
smoking. SULT1A1 is involved in the activation of some carcinogens and the inactivation 
(detoxification) of others, this dual role of the enzyme indicates the complexity of the issue. 
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We also observed that there is no significant link between the SULT1A1 genotype 
(Arg213His) and age, these results are different from the report by Coughtrie et al [6] who 
domenstrated a statistically significant increase in the SULT1A1*Arg213 allele(s) compared 
to SULT1A1*His213 with increasing age. In future epidemiological studies it is important to 
study the function of SULT1A1 in more detail taking into account the corresponding 
environmental exposure. 
In conclusion, our results indicated that the SULT1A1 (G638A) single nucleotide 
polymorphism investigated in this study is not a genetic susceptibility factor for the 
development of oesophageal cancer in Sudanese population. 
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Table I: The genotype prevalence and allele frequencies of SULT1A1 in the Sudanese 
subjects 
  
                       Cases          Controls  
Characteristic                      n (freq)          n (freq)              AOR (95% CI) p-value 
 
 
SULT1A1 genotype  
  
SULT1A1*1/*1            74 (66)          137 (70)                                
SULT1A1*1/*2            36 (32)            56 (29)             1.2 (0.72-1.97) 0.5     
SULT1A1*2/*2               2 (2)                1 (1)               3.7 (0.33-41.5) 0.3 
Total             112           194 
 
Allele frequencies 
SULT1A1*1                        184 (82) 320 (85) 1.00 
SULT1A1*2                            40 (18)            68 (15) 0.97 (0.75-1.29) 0.918 
Total              224  388  
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Table II: Allele frequencies of SULT1A1 gene among the study Linguistic Groups 
 
       Patients N(freq)                                   Controls N(freq) 
 
Allele                         AA         NS         NK                         AA          NS        NK 
         
 
SULT1A1*1       50 (82)       21(84)      3 (71)             74 (81)       27(86)        25(95) 
  
SULT1A1*2          26 (18)        8 (16)     4(29)               43 (19)       11 (14)         3 (5)    
 
AA = Afro-Asiatic  
NS = Nilo-Saharan                            
NK= Niger-Kordofanian   
 
      
 
